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The management of anxiety: 
Counseling and pharmacotherapy 
Changing the patient's 
perspective 
In the management of anxiety, the 
negative feelings the patient has about 
himself and his behavior may often be 
altered in a positive manner by discus-
sion, counseling and reassurance. 
Changing the patient's perspective is 
often the first significant step toward 
helping him to learn more appropriate, 
less anxious ways of living. The physi-
cian recognizes that the patient has cer-
tain positive qualities and he utilizes this 
"healthy core" to effect constructive 
change in outlook and life-style. When 
excessive anxiety is reduced through 
such a psychotherapeutic approach, 
there is no need for adjunctive psycho-
tropic medication. 
The patient 
and his milieu 
The physician 
may also take steps 
to identify and mobi-
lize constructive 
factors in the patient's•• 
over-all environment- a motherly 
neighbor, a dependable friend, a com-
munity club- that could furnish favor-
able experiences and thereby help 
reduce his anxiety. A change in environ-
ment to remove undesirable influences 
or modifications in the patient's work, 
personal associations and recreational 
activities may be indicated. 
Short-term psychotherapy 
A great deal may be accomplished 
for the anxious patient in regular thera-
peutic sessions lasting as little as 10 to 
15 minutes. These may be scheduled for 
one to four times monthly over a speci-
fied period, depending on the level of 
the patient's anxiety and the problems 
involved. Many interested physicians 
have gained increasing skill in this area 
through postgraduate training and 
experience. 
The adjunctive role of 
pharmacotherapy 
When counseling and other non-
pharmacologic measures do not prove 
sufficiently effective, pharmacotherapy 
can provide a valuable adjunct to other 
measures. An effective antianxiety 
agent can help foster 
the necessary rapport and com-
munication between physician and pa-
tient. The drug chosen should have a 
wide margin of safety and be relatively 
free of undesirable side effects. It should 
be compatible with other agents required 
in the patient's total medical regimen. 
When the patient's anxiety has been 
reduced to manageable levels, pharma-
cotherapy should be terminated. 
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Therapeutic action favors 
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Introduction 
This issue of the MCV /Q is a continuation of 
the first issue of this year, which was devoted to 
the subject of Immunology and the Rheumatic 
Diseases. Many of the papers presented at the 45th 
Annual McGuire Lecture Series were published in 
the first issue and this will complete those papers 
which were submitted for publication. In addition 
to subjects in the fields of juvenile rheumatoid arthri-
tis, ankylosing spondylitis, and infectious arthritis, 
papers covering immune complex reactions in SLE 
as well as delayed hypersensitivity are included. Be-
cause of recent advances in the study of histocom-
patibility antigens (W-27) in patients with connective 
tissue diseases, this subject is also discussed in this 
issue. 
ROBERT IRBY, M.D. 
Professor of Medicine 
Department of Medicine 
Medical College of Virginia 
Virginia Commonwealth University 
Viruses and the Connective Tissue Diseases* 
MORRIS ZIFF, M.D ., Ph.D. 
Rheumatic Diseases Unit, Department of Internal Medicine, 
University of Texas Southwestern Medical School, Dallas 
A number of observations in the last few years 
have attracted attention to the possibility of viral 
infection in systemic lupus erythematosus ( SLE). 
One of these is the occurrence of interwoven tubular 
structures, usually in the endothelial cells of the 
kidney but also in the lymphocytes and in fibroblasts 
when SLE skin fibroblasts are cultured. These tubu-
lar structures have resembled viruses (they were 
thought by thei~ discoverers to be myxo- or para-
myxoviruses), but it has been argued ( 1) that 
they are not viruses because of their size and ap-
pearance and because they have been produced in 
tissue cultures from subjects who do not have SLE; 
they occur in many other conditions which are not 
related to SLE. These tubular structures do not 
occur, however, in rheumatoid arthritis (RA). The 
conclusion, at this point, would seem to be that 
they are not viruses. Nevertheless, from their ran-
domness and their odd app,earance, it seems likely 
that we may be seeing the effects of a virus, per-
haps a very common ¥irus, on the endoplasmic 
reticulum of the cell. 
There has been a group of papers in which the 
point has been made (2, 3, 4) that the titers of a 
number of viral antibodies (usually myxo- and para-
myxoviruses) am somewhat elevated in patients 
with SLE. It has been argued that this simply 
represents the overall hyper-y-globulinemia of SLE, 
although we have not noted the relationship with 
y-globulin levels. It should be pointed out that there 
has been no outstanding elevation of any particular 
viral antibody titer. The antibody titer to measles, 
an RNA virus, has been consistently elevated to a 
significant degree. This may mean that antibody to 
this virus cross-reacts well with an unidentified RN A 
virus which is actually involved. 
* Presented by Dr. Ziff at the 45th Annual McGuire 
Lecture Series, November 9, 19'73, at the Medical College 
of Virginia, Richmond. 
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Cellular Immunity in SLE. Hahn and co-
workers ( 5) have reviewed the evidence for re-
duced delayed hypersensitivity in SLE. About half 
of investigators have noted decreased skin test reac-
tions in this disease. Patients with SLE also tend 
to develop lymphomas somewhat more commonly 
than expected. Presumably these patients do not 
have adequate immunologic surveillance for rejec-
tion of lymphomas on the basis of diminished cellu-
lar immunity. 
Regarding cellular immunity, it is known that 
thymus-derived lymphocytes undergo blastic trans-
formation and produce lymphokines. When the T 
cell has been stimulated, it can also subserve the 
antigen to stimulate B lymphocytes (bone marrow-
derived) to produce antibody. 
With regard to the possible role of a virus in 
SLE and the fact that depressed cellular immunity 
seems to be present, it is fairly well accepted that 
virus infections, in general, decrease delayed hyper-
sensitivity as measured by skin tests and by the 
response of the circulating T cells of the infected 
patient to mitogens like PHA and concanavalin. 
Also, if one adds a virus like rubella to lymphocyte 
cultures, the capacity of the T cells in that culture 
to undergo a response to mitogenic agents is dimin-
ished. 
As is well known, the New Zealand Black 
(NZB) mouse, particularly its F 1 hybrid, is an 
excellent model for SLE. The NZB F 1 hybrid mouse 
has also been shown to have decreased cellular 
immunity ( 6). It has a decreased capacity to in-
duce graft-versus-host disease in a recipient mouse 
strain. There is also a decreased responsiveness to 
mitogenic agents and a high incidence of lymphomas. 
For unexplained reasons, T cells in man form 
rosettes with sheep red blood cells. These rosettes 
represent a measure of the T cells circulating in the 
blood. Wybran and Fudenberg (7), using this 
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method, found that patients with viral infections 
have reduced numbers of circulating T lymphocytes. 
In our laboratory, Drs. Hurd and Giuliano have 
observed decreased numbers of spontaneous rosette-
forming cells in patients with SLE suggesting de-
creased cellular immunity. This could be a result of 
coating with an immunosuppressive globulin or a 
true deficiency of T cells. 
Autoantibody Formation. It should be pointed 
out that in SLE, we are concerned not as much with 
T cell function as with the results of B cell activity 
since these cells produce autoantibodies such as anti-
DNA, both double- and single-stranded, antinuclear 
antibody, anti-RNA, both double- and single-
stranded, as well as other types of autoantibodies. 
Are such autoantibodies found in virus infections? 
Two conditions stand out-one, infectious mono-
nucleosis, an EB virus infection, and the other, 
cytomegalovirus infection. In these conditions, we 
see antinuclear antibody, rheumatoid factor, mixed 
cryoglobulins, Coombs autoantibodies, and so forth. 
The NZB mice are infected with murine leu-
kemia viruses. This strain, unlike other strains, does 
not develop tolerance to the murine leukemia viruses 
and eventually develops antibodies to these viruses. 
These form immune complexes which circulate in 
the blood and in time the mice develop proteinuria. 
The immune complexes eventually deposit in the 
basement membrane of the kidney. If NZB F 1 
hybrids are injected with nonleukemogenic viruses 
such as LCM, which is an RNA virus, or with 
polyoma, which is a DNA virus, antinuclear anti-
body is enhanced, the glomerulonephritis is aggra-
vated and the mortality rate goes up ( 8). These 
viruses, it appears, exert an adjuvant effect in stimu-
lating autoantibody formation. Nucleic acids are 
known to have adjuvant effects. Weight for weight, 
the RNA of the tubercle bacillus is as effective an 
adjuvant as the tubercle bacillus itself (9). Powell 
and Steinberg (10) have examined the adjuvant 
effects in the NZB-NZW mouse of poly I-poly C, 
a synthetic double-stranded RNA, and have found 
an increase in antibody, not only to double-stranded 
RNA, but also an increase to DNA. Cone and 
Johnson (11) have shown that poly A-poly U in-
creased the antibody response against sheep red 
blood cells. One may speculate from these kinds 
of results that the viral nucleic acids may also have 
an adjuvant effect on both antibody and autoanti-
body formation. 
It appears likely that if a virus were to be the 
cause of SLE, it would be so by affecting T lymphocyte 
function. In our laboratory ( 12), we have demon-
strated that T cells produce a relatively low molecu-
lar weight factor, which has a stimulatory effect on 
antibody formation by B cells. Fialkow, Gilchrist 
and Allison ( 13) have shown that T cell stimulation 
can lead to autoantibody formation. F1 hybrid mice 
injected with parental cells undergo a graft-versus-
host reaction in which the donor T cells proliferate. 
These mice develop antinuclear antibody after each 
injection of T cells, presumably because of the 
elaboration of a helper factor by the proliferating T 
cells. 
There is also evidence that a suppressor popula-
tion of T cells exists which presumably inhibits 
autoantibody formation. The first evidence for sup-
pressor T cells came from our laboratory ( 14) in 
a study of the effect of antilymphocyte globulin on 
the immune response of rabbits. When rats were 
treated with this agent, the antibody response to 
keyhole limpet hemocyanin was increased instead 
of reduced. This result has been interpreted by 
others (15) to indicate that there is a type of T 
cell whose function is to suppress the antibody 
response. Subsequently, Baker and co-workers ( 16) 
showed that there was an increased response to 
pneumococcal polysaccharide in mice upon treat-
ment with antithymocyte serum. 
Recently, Steinberg and co-workers ( 17) 
showed that neonatal thymectomy of NZB mice 
accelerated the formation of anti-DNA antibodies 
and that this change could be reversed by grafting 
these mice with one-week old thymuses, but not 
with ten-week old thymuses. Suppressor T cells 
presumably are lost in the NZB F 1 hybrid at an 
early age. This seems to be the cause of the aggra-
vated form of the disease observed in thymectomized 
animals. 
It is well established that autoantibodies develop 
in the aged ( 18). Phytohemagglutinin responsive-
ness, which is a measure of T cell function, also de-
creases. These changes may reflect a loss of suppres-
sor T cells with age in man. When Teague and Friou 
( 19) administered syngenic thymocytes from young 
mice to older mice who were producing antinuclear 
antibodies, these antibodies disappeared, suggesting 
that suppressor T cell function had been restored. 
The explanation for these phenomena, most clearly 
enunciated by ·Allison ( 20), is that we are dealing 
with a particular type of tolerance in the normal 
state which does not permit autoantibodies to form. 
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This tolerance resides in the T cell, as originally sug-
gested by Weigle (21). The B cells which produce 
antoantibody are not tolerant and when they are 
stimulated by helper substance from helper T cells 
or freed from the suppressive action of suppressor 
T cells, they become free to synthesize autoantibody 
in the presence of autoantigen. In speculating about 
the role of a virus in autoimmune phenomena, one 
might suppose that an infected individual would have 
T cells sensitized to the causative virus, whatever 
virus that might be. This virus could then stimu-
late these sensitized T cells to produce a helper 
substance. As a result, potentially responsive 
(nontolerant) B cells would gain the capacity to 
produce autoantibodies. Thus, viruses might act as 
adjuvants for autoantibody formation by stimulating 
sensitized T cells to produce helper substances, 
which could then stimulate B cells to produce auto-
antibody in the presence of autoantigen. They could 
also interfere in some unexplained manner with the 
suppressor effect of suppressor T cells by producing 
a broad interference with T cell function since, as 
mentioned, T cell levels are, in fact, low in the virus 
diseases ( 7 ) . 
Another interesting line of evidence which 
should be mentioned comes from the studies of 
Lewis and co-workers (22) who have injected 
filtered suspensions of spleens of dogs with SLE 
to CA F 1 mice. These mice have, as a result, de-
veloped antinuclear antibodies. This finding suggests 
the presence of a filterable agent, probably a virus, 
in the affected donor dogs, having the capacity to 
produce antinuclear antibodies. 
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The "Three R's" of Delayed Hypersensitivity* 
DAVID HORWITZ, M.D. 
Associate Professor, Rheumatology Division, Department of 
Internal Medicine, University of Virginia School of Medicine, 
Charlottesville 
Delayed hypersensitivity is one of several im-
mune responses initiated by thymus-derived (T) 
lyrriphocytes. Other functions of T cells are listed 
in Table . 1 and summarized in reference 1. The 
mononuclear infiltrate of delayed hypersensitivity is 
a collaborative phenomenon between T lymphocytes 
and monocytes. This collaboration can be separated 
into components which I have chosen t6 call the 
"three R's'~ of delayed hypersensitivity. In this dis-
cussion I will define these "three R's" and examine 
the usefulness of this concept in clinical medicine. 
Hematoxylin and eosin sections of skin biopsied 
48 hours after intradermal injections of antigen 
characteristically show mononuclear cells around 
blood vessels and in connective tissue. As early as 
1951, however, Gell and Hinde (2) reported that 
the monocyte was the principal participant in the 
skin site. In 1963, McCluskey (3), using radio-
isotopic techniques, found that 90% of the mono-
nuclear cells in the reaction site were blood-borne 
and originated from cells that had divided 48 hours 
previously. Subsequently, cell transfer studies have 
provided conclusive evidence that the rapidly divid-
ing cells originated in the bone marrow and were 
precursors of the blood monocyte. Tiie evidence is 
as follows: 1) Injection of immune lymphocytes into 
nonimmune, irradiated recipients failed to transfer 
positive skin reactions ( 4); 2) Injection of bone 
marrow cells from nonimmune donors to sensitized, 
irradiated animals resulted in positive responses ( 5); 
3) Local injection of nonimmune macrophages into 
the skin of irradiated, sensitized recipients elicited 
positive responses in these areas ( 6). 
These studies indicated that two populations of 
cells are required to elicit delayed hypersensitivity. 
* Presented by Dr. Horwitz at the 45th Annual 
McGuire Lecture Series, November 8, 1973, at the Medical 
College of Virginia, Richmond. 
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The first are radioresistant, which were later defined 
as long-lived, T lymphocytes. The second population 
are cells of the monocyte/ macrophage system and 
are derived from radiosensitive precursors in the 
bone marrow. 
From this information we can develop a con-
cept of delayed hypersensitivity consisting of three 
components (Table 2). First, sensitized T lympho~ 
cytes, perhaps with some help from macrophages, 
recognize intradermally injected antigen. Secondly, 
antigenic contact triggers a response in sensitized 
lymphocytes. Within a few hours these cells release 
soluble mediators (7) called Iymphokines into the 
environment and later, activated small lyrriphocytes 
transform into blasts and proliferate. Thirdly, through 
the amplifying effects of lymphokines, such as migra-
tion inhibitory factor (MIF) and monocyte chemo-
tactic factor (MCF), other leukocytes, predominantly 
monocytes, accumulate at the skin .test site and 
comprise the reaction of delayed hypersensitivity. 
This mononuclear infiltrate is similar to that of any 
other chronic inflammatory reaction. The triggering 
event, however, is an immunologically specific re-
sponse of T lymphocytes. 
Techniques are available to evaluate each of the 
"three R's." The number of circulating T cells avail-
able for antigen recognition can be quantitated by 
several methods. The most widely used method at 
this time is a rosette technique. When sheep erythro-
cytes are incubated with human lymphocytes at 4 °C, 
the erythrocytes form rosettes around T cells ( 8). 
Secondly, heterologous anti-T lymphocyte serum has 
been developed (9) and may be used to quantitate 
T cells either by immunofluorescence or cytotoxicity. 
The second component, response to antigen, 
can be evaluated by measuring the lymphocyte pro~ 
Iiferative response to antigen. In these studies 
lymphocytes are cultured with test antigen for five-
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TABLE 1 
THYMUS-DERIVED LYMPHOCYTE FUNCTIONS 
1. Delayed hypersensitivity 
2. Activation of macrophages to resist infection 
3. Rejection of allografts and tumors 
4. Regulation of antibody production by B cells 
to-seven days and proliferation is assayed by measur-
ing incorporation of a radiolabeled DNA precursor. 
Alternatively, one can measure lymphokine 
production from antigenically stimulated lympho-
cytes. Migration inhibitory factor has received the 
most attention (7). Various techniques to measure 
MIF have been developed which are based on the 
inhibition of leukocyte migration by the culture 
supernatants of stimulated lymphocytes. The method 
of Rocklin and David (10) correlates well with 
delayed hypersensitivity. These workers use guinea 
pig peritoneal macrophages as effector cells. Other 
workers have substituted human "buffy coat" leuko-
cytes for guinea pig macrophages ( 11 ) . Results 
obtained with these cells as the indicator cells, how-
ever, did not always correlate with cutaneous skin 
reactivity to antigen (12). 
I prefer to measure MCF rather than MIF, 
because both response and reaction can be evaluated. 
With this technique we can detect mediator produc-
tion from a given patient's lymphocytes and also 
evaluate the capacity of that subject's monocytes to 
respond to bis own mediator. With a method to 
measure leukocyte chemotaxis, we can evaluate both 
lymphocyte and monocyte function. 
To perform this technique a chamber is divided 
into an upper and lower compartment by Nuclepore® 
membrane. Monocytes are placed in the upper cham-
ber and the chemotactic stimulants in the lower 
chamber. The specific migration of cells from the 
upper to the lower surface of the membrane filter 
is quantitated ( 13). 
These in vitro methods can be used to define 
the component that is defective in patients with 
impaired delayed hypersensitivity. Lymphocytes from 
children with a congenitally absent thymus gland 
(the DiGeorge syndrome and Nezelof syndrome) 
fail to form rosettes with sheep erythrocytes or to 
proliferate in response to mitogens. These children, 
then, do not have sufficient T lymphocytes capable 
of antigenic recognition. 
Impaired cell-mediated immunity in chronic 
mucocutaneous candidiasis may be due to several 
defects, either .in a response or reaction. Patients 
with this disease usually have adequate numbers of 
circulating lymphocytes but may have selective de-
fects in lymphocyte or monocyte function. In some 
subjects, blast transformation is intact but MIF is 
absent ( 14). In others, mediator production is intact, 
but these patients' lymphocytes fail to proliferate in 
response to antigen (15). Finally, Snyderman (16) 
reported a patient with chronic mucocutaneous candi-
diasis whose monocytes responded poorly to a 
chemotactic stimulus. Although it is tempting to 
speculate that the defects detected with in vitro 
TABLE2 
DELAYED HYPERSENSITIVITY 
A COLLABORATIVE PARTICIPATION OF LYMPHOCYTES AND MACROPHAGES 
IN AN IMMUNOLOGICALLY SPECIFIC INFLAMMATORY REACTION 
Component Assay System 
1. The recognition by small (thymus-derived) 
lymphocytes of material which is antigenic to the host. 
2. A response of sensitized lymphocytes as detected by the 
release of soluble factors (lymphokines) and later by 
cell division. 
Quantitation of T lymphocytes by: 
1. Spontaneous rosettes without sheep erythrocytes. 
2. lmmunofluorescence or cytotoxicity using heterologous 
antihuman thymocyte serum. 
Generation of lymphokines 
1. Migration inhibitory factor (MIF) 
2. Macrophage chemotactic factor (MCF) 
Blast transformation and proliferation 
3. A mononuclear inflammatory reaction, consisting Monocyte response to MCF 
predominantly of "activated" macrophages, which "Skin-window" assay 
leads to the attack, destruction, and sequestration of 
autologous or foreign materials. 
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techniques accurately reflect an in vivo disturbance, 
the data must be interpreted with appropriate caution 
at this time. 
Delayed hypersensitivity may be impaired in 
conditions without a demonstrable defect in cellular 
function . Serum factors inhibit lymphocyte function 
in certain diseases and several examples are listed 
in Table 3. The role of these serum inhibitors has 
not been defined. Moreover, primary disorders of 
lymphocyte function have not been differentiated 
from secondary effects caused by serum factor in 
many diseases with impaired cellular immunity. 
Recent studies from this laboratory suggest that 
anergy in such diverse diseases as systemic lupus 
erythematosus (SLE) and primary intracranial tu-
mors ( 17) is caused by serum inhibitors rather than 
defective cells. Fractionation of inhibitory serum 
in patients with each of these diseases revealed an 
IgG factor that broadly suppresses reactivity of 
allogeneic as well as autologous lymphocytes. This 
inhibitory lgG factor has been named lymphocyte 
regulatory immunoglobulin (LRG) and increased 
LRG in SLE may, in part, explain decreased delayed 
hypersensitivity. Patients with SLE and other dis-
eases also have a lymphocytotoxic antibody that 
may depress cell function. 
In summary, I have attempted to develop a 
working model of delayed hypersensitivity that may 
be useful in understanding areas puzzling to the non-
immunologist. The reader is urged to ask the follow-
ing questions in order to evaluate scientific papers 
dealing with defective cellular immunity in various 
diseases. First, did the patients studied have adequate 
numbers of circulating lymphocytes and monocytes? 
Secondly, did the methods used evaluate a single 
component of delayed hypersensitivity or were sev-
eral components analyzed? Finally, did the authors 
distinguish a primary cellular defect from secondary 
TABLE 3 
DISEASES WITH SERUM INHIBITORS OF LYMPHOCYTE FUNCTION 
1. Hematologic and solid tumors 
2. Systemic lupus erythematosus 
3. Tuberculosis 
4. Multiple sclerosis 
5. Hepatitis 
6. Lepromatous leprosy 
7. Ataxia telangiectasia 
8. Multiparous women 
9. Multiple transfusions 
humoral effects? Separation of delayed hypersensi-
tivity into "three R's" may be helpful in organizing 
and understanding present information. 
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Immune Comp.lex Reactions in Systemic Lupus 
Erythematosus* ** 
JOHN ST AIGE DAVIS, IV, M.D. 
Professor of Internal Medicine, Chief of the Division of 
Rheumatology, University of Virginia School of Medicine, 
Charlottesville 
We should first try to define systemic lupus 
erythematosus (SLE). Table 1 lists criteria proposed 
by a committee of the American Rheumatism Asso-
ciation ( 1). If four of these 14 major criteria are 
positive, then there should be about 98% specificity 
for SLE. There are clearly many facets to this dis-
order. Let us consider mechanisms that might ac-
count for a multisystem disease such as this. 
A good model is that of experimental serum 
sickness. Though Germuth (2) provided much of 
the renewed impetus to study serum sickness in the 
'SO's, it is Dixon (3) who has fully explored the 
variables of immune complexes and disease. 
When a rabbit is given a single intravenous 
injection of bovine serum albumin (BSA) labelled 
with 1811, one notes disappearance of the BSA in 
serum over a period of about 13 days. First there 
is a rapid fall, then an equilibrium dev~lops; and 
then suddenly there is total disappearance of the 
injected BSA. Coincident with the rapid disappear-
ance of BSA, one can measure antigen-antibody 
complexes. Finally, free antibody to BSA is detected. 
During the period when these immune complexes are 
found, the rabbits develop heart disease, arthritis, 
nephritis, and other manifestations. It is a self-
limited disease, however, and when free antibody 
is found the disease clears up. Hemolytic comple-
ment (C) has been measured also; with the appear-
ance of immune complexes, the C level falls, later 
* Presented by Dr. Davis at the 45th Annual McGuire 
Lecture Series, November 8, 1973, at the Medical College 
of Virginia, Richmond. 
**Supported in part by the USPHS Grant No. 5R01-
AM11766 and a grant from the John A. Hartford Founda-
tion, Inc. 
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returning to normal. This then is the model of 
experimental serum sickness in the rabbit; what 
about immune complexes in man? 
We are postulating that many manifestations 
of SLE probably result from deposition of circulating 
immune complexes. Numerous data are now avail-
able which would support this concept. What can 
we now do to find these eomplexes and characterize 
them? If we can show what is in these complexes, 
we should know something more about pathogenesis. 
Table 2 lists some of the methods that are 
available today. These methods are mostly limited 
to research laboratories. I have listed these methods 
as either analytical or preparative. Cryoprecipitation 
is both analytical and preparative; furthermore, 
cryoprecipitates are easily measured since all one 
needs is a refrigerator and a centrifuge. Recent 
studies by Mcintosh et al. ( 4) suggest that cryo-
precipitates correlate well with immune complex 
formation in rabbits; evidence in man is not as 
convincing since it is difficult to recover a specific 
pathogenetic antigen in SLE cryoprecipitates. 
Clq precipitation was first described by Agnello 
et al. (5); here one utilizes purified Clq to pre-
cipitate with serum factors in double diffusion 
systems. Rheumatoid factor (RF) can be used in 
the same way. Efforts in our lab are now being 
directed toward an analysis of the characteristics of 
Clq reactive factors. It is of interest that Clq and RF 
seem to detect different substances in serum. Passive 
agglutination of RF-coated cells is another method 
which detects complexes, as is complement fixation 
(which is a way of interpreting "anticomplementary 
serum"). Recent work in England has shown com-
plement fixation and Clq precipitins not only in 
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TABLE 1 
PRELIMINARY CRITERIA FOR CLASSIFICATION OF SLE 
!. Facial Erythema (Butterfly Rash) 
2. Discoid Lupus 
3. Raynaud's Phenomenon 
4. Alopecia 
5. Photosensitivity 
6. Oral or Nasopharyngeal Ulceration 
7. Arthritis without Deformity. [One or more peripheral 
joints involved with any of the following in the absence 
of deformity: a) Pain on motion, b) Tenderness, c) 
Effusion or periarticular soft tissue swelling.] 
8. LE Cells 
9. Chronic False-Positive STS 
10. Profuse Proteinuria 
11. Cellular Casts 
12. One or both of the following: a) Pleuritis, b) Pericarditis 
13. One or both of the following: a) Psychosis, b) 
Convulsions 
14. One or more of the following: a) Hemolytic anemia, b) 
Leukopenia c) Thrombocytopenia 
SLE serum but in sera from patients with dermatitis 
herpetiformis, ulcerative colitis, regional enteritis, 
and coeliac disease ( 6, 7). Lymphocyte inhibition 
is another technique recently reported: B cells, 
which kill sensitized tumor cells, are inhibited by 
serum containing aggregates or immune complexes 
( 8). Platelets can also be agglutinated by com-
plexes. 
Cryoprecipitation is, at the same time, a pre-
parative method. Likewise Clq can be linked to 
Sepharose® columns through cyanogen bromide to 
facilitate removal of Clq precipitins from serum for 
analysis (9). Hopefully, the immune complexes and/ 
or aggregates will stick and everything else will wash 
through; then the bound material can be eluted off 
TABLE2 
DETECTION OF CIRCULATING IMMUNE COMPLEXES AND / OR 
AGGREGATES 
Analytical 
Cryoprecipitation 
Clq detection in agarose gel 
RF detection in agarose gel 
or reverse hemagglutina-
tion 
Complement fixation 
Lymphocyte inhibition 
Platelet agglutination 
Preparative 
Cryoprecipitation 
Cl q precipitation 
Adsorption to columns of 
insoluble Clq 
Isolation by column 
chromatography 
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with salt and the residue analyzed. Serum can also 
be run directly through agarose columns with ex-
clusion of large molecular weight materials. In sum-
mary, the main point here is that many methods are 
being developed to find and characterize aggregates 
and complexes; the simplest method is probably 
cryoprecipitation. 
Figure 1 shows various factors which we mea-
sured longitudinally in one SLE patient several years 
ago. The relationship between serum cryoglobulins 
and C levels is particularly noteworthy (our normal 
range for serum hemolytic complement is 34-48 
CH50 units/ ml) and one can clearly see the re-
ciprocal relationship between C and cryoglobulin 
during the time span. This negative correlation is 
not always seen but usually is. 
Figure 2 shows findings in another patient. 
Here the C level is first found in the normal range 
at a time when no cryoglobulins are seen. As the 
cryoglobulins appear, C levels begin to fall. It should 
also be noted that the antinuclear factor (ANF) 
remained fairly constant during this time period, 
though no titers were done. It has been our experi-
ence that when we use a 1 :4 dilution of serum for 
the ANF test, little change in ANF can be noted 
between acute exacerbations and remissions of SLE. 
With prolonged remission, however, the staining may 
become less intense, though the ANF rarely dis-
appears entirely in SLE patients. RF titers (usually 
low titers, when found) also tend to remain quite 
constant in SLE patients, though RF was not found 
in either of the patients shown in these figures. 
c 
Lupus Patient Ca 
ANF [ 
RF 
4+ 4+ 4+ 4+ 4+ 3+ 4+ 4+ 4+ 4+ 4+ 
so 
·····~ CRYOGLOBULIN 
0-----0 COMPLEMENT 
40 4 + li!l PROTEINURIA 
30 3+ 
Cryo 
20 2 + 
10 1+ 
12 1 2 3 4 
1968 
s 6 7 8 9 
1969 
Months 
0 0 0 0 0 
6 ······6····4 
Proteinurio 
2 3 4 
1970 
I 
-- Ir 
Fig. I-Laboratory findings in a patient with SLE over a 
16-month period. The reciprocal relationship between C 
and cryoglobulins is noteworthy. Antinuclear factor and 
proteinuria are relatively stable during this time. 
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Fig. 2-Laboratory findings in another patient with SLE. 
Very little proteinuria is noted even when the C level is 
low and large amounts of cryoglobulin are found. 
Clq precipitins have been found primarily in 
SLE patients with low serum C levels according tb 
one report (10) . In a group of 30 SLE patients with 
low C levels, 23 were positive for Clq precipitins; 
of those SLE patients who had normal C levels none 
were positive for Clq precipitins. A few p~tients 
with miscellaneous diseases were positive ( 6/ 150) . 
Table 3 shows our results: Of 908 total sera 
tested for Cl q precipitins, 19 % were positive. (These 
sera came from patients who had a variety of diseases 
and were mainly suspected of having a connective 
tissue disease or vasculitis.) Of the lupus sera, 15 % 
were positive and of the lupus patients, 43 % were 
positive on at least one occasion. Sera from patients 
with other diseases were positive 27 % of the time, 
the 28 % positivity of nonlupus patients reflecting 
the fact that many of these patients were only 
studied by this technique on one occasion . Of par-
ticular note is the finding of Clq precipitins in other 
diseases besides SLE-a finding supported by other 
investigators ( 6, 7, 10) . 
TABLE 3 
Clq PRECIPITATION 
Total #Positive 3 Positive 
Total Sera 908 174 19 
Lupus Sera 601 90 15 
Lupus patients 95 41 43 
Other Sera 307 84 27 
Other patients 216 61 28 
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TABLE 4 
Clq PRECIPITINS VS. CRYOGLOBULINS 
# Positive 3 Positive 
Total Sera (106) 16 15 
Lupus Sera (74) 11 15 
Other Sera (32) 5 16 
Cryoglobulins (106) 0 0 
Cryo. Supernatants (106) 24 23 
Lupus (74) 18 24 
Other Sera (32) 6 19 
Results of the Clq precipitin test as it relates 
to sera with cryoglobulins ate shown in Table 4. 
One notes that of the 160 sera tested here, 16 were 
positive for Clq precipitins; aild of these 16 sera, 
11 were SLE seta and 5 were other disease sera. 
Only some of these sera had cryoglobulins, but we 
treated them all as if they did-that is, they were all 
centrifuged after 48 hours in the cold and the super-
natant transferred to another tube for testing against 
Clq. The cryoprecipitates, whether visible or not, 
were resolubilized at a ten-fold concentration and 
also retested against Clq. No cryoprecipitates showed 
a precipitin line, suggesting that 1 ) there was not 
enough material, 2) the material did not react with 
Clq, or 3) that the cryoprecipitate was already satu-
rated with bound Clq. Of more importance, how-
ever, was the finding that of the 106 supernatants, 
24 (instead of 16) were now positive. Ali of the 
16 sera which were positive originally remained pos-
itive when the supernatant was checked and eight 
sera which were originally thought to be negative 
were now positive after removal of any cryoprecipi-
tates. These studies have suggested to us that cryo-
globulins have properties, at least in part, distinctive 
from Clq precipitins. Possibly the cooling and cen-
trifugation of certain sera lead to aggregation of small 
complexes that do not spin down as cryoglobulins, 
but do subsequently react with Clq, even at room 
temperature! 
For several years, we have been interested in 
how RF might modify IgG aggregates or immune 
complexes in human disease ( 11, 12). We have 
wondered whether RF might affect the deposition 
or metabolism of complexes by changing their size 
or their physicochemical properties in some other 
way. Small, soluble complexes might be made in-
soluble by RF; this might serve a protective function 
or a pathogenetic function depending on the circum-
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Precipitation of 3H-DNA 
by SLE Serum with RF-lgM and Controls 
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(F.W. 8/ 12/ 70) 
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Fig. 3-Effect of lgM rheumatoid factor on bNA-anti-
DNA complexes. Constant amounts of IgM [either control 
(C) or containing rheumatoid factor (RF)] are added to 
constant amounts of anti-DNA (SLE) serum and increasing 
amounts of . DNA. Much more radioactive DNA is found 
in the precipitate when RF is added than in appropriate 
control systems. 
stances ( 13). Figure 3 shows that RF has the 
capability of precipitating partially soluble DNA-
anti-DNA complexes form!!d in vitro when one adds 
increasing amounts of ~abelled DNA to an SLE 
serum. It can be seen that much more precipitate 
is formed (based on counts of radioactive DNA in 
the precipitate) in the presence of RF than whert 
the complexes are formed in the presence of control-
lgM or buffer alone. We interpret these findings to 
mean that RF can interact with and precipitate 
DNA-anti-DNA complexes, thus converting these 
partially soluble complexes into insoluble complexes. 
As mentioned above, such a function for RF in vivo 
could be either protective or damagihg. 
Figure 4 shows effects of RF on cryoprecipitates. 
It would appear that RF has the potential for either 
increasing or decreasing cryoprecipitation, probably 
depending on characteristics of the cryoprecipitate. 
Conceivably one might be dealing with a system 
analagous to an antigen-antibody complex which 
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would precipitate at equivalence but would resohi-
bilize in both antigen and antibody excess. 
Table 5 shows the sort of data being accumu-
lated currently on patients seen at the University qf 
Virginia Lupus Clinic. In the serum of this patient 
before treatment, a Clq precipitin was found, along 
with 3+ cryoglobulins, strong anti~DNA activity, a 
low C level, and strong ANF staining: After institu-
tion of steroid treatment, the Clq precipitin dis-
appeared, but then we found material in the serum 
reacting with RF! (This often-seen reciprocal rela-
tion is of great interest to us, but we don't under-
stand it.) Cryoglobulins disappeared (as did the 
anti-DNA antibodies) and at the same time the 
serum C level returned to normal. Since starting 
treatment, the patient has done well, and we have 
continued to be on the lookout for. the reappearance 
of those factors associated with disease activity as 
we slowly lower the steroid dose. 
Table 6 is an analysis of serum material bound 
to Clq on a cyanogen bromide Sepharose® column. 
1.2 
1.05 
0 .9 
mg. of o.6 
Cryoprotein 
0 .3 
0.15 
Cryoglobulin in Lupus Sero before 
ond after addition of RF 
(lml RF added to 2ml Lupus Sera) 
Cryo Cryo 
+ 
RF 
Wa 
(1 / 8 / 70) 
Cryo Cryo 
+ 
RF 
Ca 
(1 / 8 / 70) 
Cryo Cryo 
+ 
RF 
Fig. 4-Effect of lgM rheumatoid factor on three SLE sera 
containing cryoglobulins. After addition of RF to fresh sera 
Sn and Wa, less cryoglobulin was detected after 48 hours 
at 4°C; when RF was added to serum Ca, however, more 
cryoprotein was detected. 
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TABLE 5 
S. P. (SLE) 
Complexes 
Clq RF Cr yo 
4/6/72 + 3+ 
Treatment Started 
4/ 11 / 72 + 
+ 
ND* 
4/ 13 /72 ND 
4/ 17 / 72 ND 
4/21/72 1-2+ 
5/ 2/ 72 
6/13/72 
7 / 25/ 72 
11 / 21 / 72 
* ND = Not Done 
One notes the presence in the two eluates of IgG 
and IgM but no anti-DNA or DNA. Currently, we are 
analyzing these eluates by a variety of techniques in-
cluding animal immunizations (to elicit antibodies to 
any infectious agents which might be there). Charac-
tedstics of Clq precipitins are also being compared 
with characteristics of cryoglobulins. It should be 
noted at this point that normal serum also contains 
significant amounts of material which bind to the 
Clq adsorbent. 
In summary, we can draw very few firm con-
clusions about immune complexes in patients with 
SLE. SLE patients during episodes of disease activity 
often show both cryoglobulins anq Clq precipitins 
in their sera, but in our experience, the sera may 
show only one of the factors and occasionally neither 
one is found. When cryoglobulins are removed from 
sera, Clq precipitins not only remain in the super-
natant but occasionally may be found in the super-
TABLE 6 
ANALYSIS OF ELUATES BOUND TO INSOLUBLE CIQ 
E.F. (SLE)* 
lgG (mg) 3. 12 
lgM (mg) 0 .49 
IgA (mg) 0 
Clq + 
DNA 
Anti-DNA 
RF 1:8 
Pptns. vs Clq + 
* SLE = Lupus serum eluate 
** N = Normal serum eluate 
J.D. (N)** 
0 .73 
0 . 31 
0 
Trace 
1 :8 
+ 
2+ 
Anti-DNA 
3+ 
3+ 
2-3+ 
2-3+ 
2+ 
ANF 
4+ 
ND 
ND 
ND 
1-2+ 
ND 
3+ 
3-4+ 
3-4+ 
CH50 
10 
13 
ND 
ND 
ND 
40 
53 
48 
45 
natant for the first time. This finding suggests that 
cryoglobulins and Clq precipitins are at least in part 
distinct. RF may interact with DNA-anti-DNA com-
plexes and cryoprecipitates at · least in vitro. Studies 
are in progress to furtfler characterize the material 
found in, the~e complexes. Hopefully, a particular 
antigen or a particular characteristic of SLE com-
plexes will be found which will lead to a better 
understanding of the primary cause and intermediate 
mechanisms involved in the serious disease kriown 
as SLE. 
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Ankylosing Spondylitis* 
JOHN BAUM, M.D. 
Professor of Medicine, Pediatrics, and Preventive Medicine and 
Community Health, University of Rochester School of Medicine, 
Rochester, New York 
Within the last few years, the study of anky-
losing spondylitis has produced some of the more 
remarkable new developments in the field of the 
rheumatic diseases. In modern days the disease has 
been described in Germany by Striimpell and in 
France by Marie. As a result, in Germany it is 
known as Striimpell's disease and in France as 
Marie's disease. Physicians in the United States and 
England, to be fair, call it Marie-Striimpell disease. 
It should be emphasized at this point that ankylosing 
spondylitis is not a variant of rheumatoid arthritis 
as it had been considered for a number of years. 
The term rheumatoid spondylitis is still occasionally 
used but should be completely abandoned. 
The initial diagnosis of ankylosing spondylitis 
is often a difficult one to make. The best criteria we 
have are quite simple. They are 1) limitation of 
motion of the lumbar spine; 2) pain in the low back; 
and 3) limitation of chest expansion. As you can 
see, no laboratory tests except the x-ray film are 
used and in the early stages, x-ray film examination 
may not be helpful. 
Examination of the lumbar spine in some studies 
shows that limitation of extension may actually be 
a better way of separating normal from abnormal 
spines ( 1), although limitation of flex ion (flattening 
of the lumbar curve) is usually what we look for 
in the back examination. Moll and Wright (2) have 
shown that lateral spinal flexion is the best way 
to distinguish between spondylitis and lumbar disc 
disease. Spondylitis will also cause limitation in this 
direction. 
The erythrocyte sedimentation rate can be 
normal in patients with ankylosing spondylitis. 
Even patients with rather marked degrees of pain 
* Presented by Dr. Baum at the 45th Annual McGuire 
Lecture Series, November 9, 1973, at the Medical College of 
Virginia, Richmond. 
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can have normal sedimentation rates while patients 
who may just show changes in the sacroiliac, hips, 
or back without pain can have a significantly elevated 
sedimentation rate. Of course, rheumatoid factor is 
not found in these patients and can be of diagnostic 
help only by its absence. 
The patient with ankylosing spondylitis is 
usually a young white male who gives a fairly 
typical story. Back pain usually wakes him up in 
the small hours of the morning. It is rare that he 
will complain of being unable to go to sleep because 
of pain. He will usually awake because of discom-
fort in the lower back and get out of bed. He may 
get relief (and go back to sleep) lying on the floor 
or sitting up in a hard back chair or sitting on the 
floor with his back against the wall. The pain fre-
quently, as with sciatica, goes down the back of the 
legs. Alternation of the radiating pain from one side 
to the other is a typical feature which helps to 
distinguish the symptoms from those produced by a 
lumbar disc protrusion. 
Examination of the x-ray films may initially 
show erosions in the sacroiliac joints and finally 
fusion, and of course, the "bamboo" spine of late 
disease is well known. The development of the 
changes in the spine can be shown diagrammatically 
so one can differentiate the syndesmophyte of anky-
losing spondylitis from the osteophyte of degenera-
tive joint disease (Fig. 1). This is taken from a 
recent article of Riley, Ansell, and Bywaters (3). 
On the left in the figure is seen the progression of 
osteophytosis and on the right, the progression of 
syndesmophytosis. The osteophyte is associated with 
disc narrowing. The bony plate is marginal and most 
importantly is horizontal as seen in stages three and 
four. It is built up at the base with subperiosteal 
bone. The base appears to lie against protruded 
disc substance. In ankylosing spondylitis, there is no 
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Reprinted by permission from Ann Rheum Dis (3 ) . 
Fi 1. 
disc narrowing or protrusion. A vertical plate is 
built up in the outer layer of the annulus fibrosis. 
These syndesmophytes will ultimately bridge in stage 
IV of the disease. 
Ankylosing spondylitis is a disease of young 
males, seen in Figure 2 where the peak in a large 
series is found to occur in the late teens and early 
20's (4, pg. 10). There is, however, a group of 
ankylosing spondylitics who start at an earlier age. 
Barbara Ansell and Eric Bywaters in Taplow, Eng·· 
land followed up 139 patients with juvenile rheuma-
toid arthritis (JRA), 55 males and 84 females, for 
at least 15 years into adult life. What was striking 
about the 55 males was that 9% of them, as they 
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went on to adulthood, developed typical ankylosing 
spondylitis. 
Joint involvement in ankylosing spondylitis is, 
of course, different from that seen in patients with 
rheumatoid arthritis. Forestier ( 4) showed (Table 
1) the high frequency of hip involvement in this 
disease when compared to patients with rheumatoid 
arthritis. In the rheumatoid, there is much more 
peripheral joint involvement. 
There are a number of complications which 
are more specific and more frequent in ankylosing 
spondylitis than in many of the other forms of 
arthritis . Most of the complications that have been 
noted are listed in Table 2. Iritis is said to occur in 
up to 20% of patients. Aortic insufficiency is usually 
seen quite late in the disease. Heart block is rarely 
seen but also probably represents the same type of 
inflammatory action in the myocardium as is seen 
in the aorta. Amyloidosis, again, is not seen 
frequently but is a recognized cause of death in 
ankylosing spondylitis-certainly more so than with 
rheumatoid arthritis. Atlantoaxial subluxation is a 
constant threat to these people with spine fusion and 
can sometimes be fatal after only moderate degrees 
of trauma. Cauda equina involvement is rarely seen 
but, again, is a well-recognized problem. Pulmonary 
fibrosis of the upper lobe is of interest because this 
fibrosis, which may be typical of spondylitics, has 
been mistaken for tumor, tuberculosis, and the like. 
NUMBER OF CASES 
40 
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From Forestier, J . et al., ( 4) . Courtesy of Charles 
C Thomas, Publisher, Springfield, Illinois. 
Fig. 2. 
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TABLE 1 
PERIPHERAL JOINT INVOLVEMENT AT ONSET* 
Ankylosing Rheumatoid 
Spondylitis Arthritis 
(200 patients) (100 patients) 
Joint % % 
Hips 42 10 
Knees 29 62 
Ankles 7 58 
Feet 12 28 
Shoulders 30 64 
Elbows 3 46 
Wrists 5 82 
Hands 7 94 
Temperomandibular 6 8 
Sternoclavicular 11 7 
* After Forestier ( 4) 
It probably accounts for some of the earlier state-
ments made about the higher frequency of tubercu-
losis in these patients. It is remarkable how good 
pulmonary function is in these men with limited 
chest expansion. A recent study indicates that im-
pairment of lung function is minimal in most of the 
patients with this disease ( 5). 
The variants of ankylosing spondylitis are shown 
in Table 3. All of these conditions can show sacro-
iliitis and indeed in some cases, go on to more exten-
sive spinal involvement quite similar to those seen in 
ankylosing spondylitis. I will mention some of these 
again later because of an interesting relationship. 
For many years, it has been felt that there were 
strong genetic features connected with ankylosing 
spondylitis. Several years ago, when I was still in 
Dallas, Morris Ziff and I, seeing our patients at 
the Veterans Administration Hospital, were struck 
by the relative rarity of ankylosing spondylitis among 
our black patients. (One of the earliest clinicians 
to note this rarity was Elam Toone in 1949.) 
He found, in a group of patients that he was 
studying in the McGuire Veterans Administration 
Hospital in Richmond, 26 white and only three 
black patients with ankylosing spondylitis ( 6). Table 
4 shows what we found in Dallas at the Veterans 
Hospital when we looked at the frequency of anky-
losing spondylitis in relation to a number of other 
disease admissions rates and the male population of 
Dallas ( 7). As you can see, although the admission 
rate to the Veterans Hospital clearly reflected the 
racial distribution of the population, there was a 
marked discrepancy in the relative ratio of patients 
TABLE 2 
COMPLICATION~ OF ANKYLOSING SPONDYLITIS 
Iritis 
Aortic Insufficiency (Aortitis) 
Heart Block (Myocarditis) 
Amyloidosis 
Atlantoaxial Subluxation 
Cauda Equina Involvement 
Upper Lobe Fibrosis 
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with ankylosing spondylitis. We were not satisfied 
with this view, thinking perhaps we might have an 
unusual situation. When data were pooled from a 
number of VA hospitals, we found a fourfold dif-
ference in the frequency of ankylosing spondylitis 
between whites and blacks. A search of the African 
literature showed that there are virtually no patients 
with ankylosing spondylitis in Africa among the 
black native population. A review of genetic studies 
in the United States indicated that the black popula-
tion of the United States has a 20-25% admixture 
of white genes. This admixture of white genes would 
very nicely account for the fact that ankylosing 
spondylitis was only found in about 20-25% of 
the expected frequency, if it had the same distribu-
tion in the blacks as it did in whites. 
This information was subsequently utilized by 
Schlosstein, Terasaki, Blues tone, and Pearson ( 8) 
at the Wadsworth VA Hospital in Los Angeles. 
The transplantation antigen known as W-27 was 
found in 8% of a caucasian population but was 
found in 88% of a group of patients with ankylosing 
spondylitis. It was also interesting to note that W-27 
is not found in Black Africans and is present in an 
approximate frequency of 4% in Black Americans. 
To further support the relationship of this antigen to 
ankylosing spondylitis, W-27 was found in eight of 
ten Black Americans with ankylosing spondylitis. 
Another and perhaps more striking correlary of 
TABLE 3 
VARIANTS OF ANKYLOSING SPONDYLITIS 
Psoriatic Arthritis 
Ulcerative Colitis 
Crohn's Disease 
Whipple's Disease 
Behcet's Disease 
Reiter's Disease 
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TABLE4 
RACIAL DISTRIBUTION OF ADMISSIONS AND OF ANKYLOSING SPONDYLITIS, RHEUMATOID ARTHRITIS, AND REITER'S SYNDROME AT 
DALLAS VETERANS ADMINISTRATION HOSPITAL 
Number White 
Males-Dallas, Texas (1960 census) 263,354 
Male Admissions (10 months, 1966) 5 , 182 
Ankylosing Spondylitis (1959- 1966) 41 
Rheumatoid Arthritis (1959- 1966) 90 
Reiter's Syndrome (1959- 1966) 7 
this data was recently presented by Rodney Blue-
stone of this group at the XIIIth International Con-
gress of Rheumatology in Kyoto, Japan (9). In 
Table 5 are seen their most recent data. As you can 
see, W-27 is found in 14 of 156 patients with 
psoriasis alone. This is just about the frequency found 
in the normal population; however, in those patients 
with psoriasis who develop spondylitis it has been 
found in four of six individuals. In patients with 
colitis who developed spondylitis, this high frequency 
was again found. Perhaps even more remarkable are 
15 out of 16 juvenile rheumatoid arthritics with W-27 
who had spondylitis. Chronic Reiter's syndrome had 
the W-27 antigen in every case. Perhaps more 
astonishing were the studies they subsequently did 
looking at patients with acute Reiter's syndrome. 
Even those who do not have spondylitis showed 
W-27 in a remarkably high frequency. 
We now seem to have a new tool for the diag-
nosis of some forms of arthritis. For example, in 
male children who develop what appears to be 
juvenile rheumatoid arthritis, looking for W-27 might 
give us a strong clue as to the future course of their 
disease. A similar use could be in suspected Reiter's 
syndrome. This has certainly opened the door to a 
most fascinating series of studies and conjectures 
TABLE 5 
Psoriasis with Spondylitis 
Psoriasis Alone 
Colitis with Spondylitis 
JRA with Spondylitis 
Chronic Reiter's with Spondylitis 
Acute and Chronic Reiter's 
Frequency of 
W-27 
4/ 6 
14/ 156 
4/ 6 
15/ 16 
8 / 8 
22/ 23 
% % White-Black 
Number Black White Black Ratio 
61, 911 81 19 4.2 
1, 227 81 19 4 .2 
3 93 7 13 . 7 
16 85 15 5.6 
4 I. 8 
about the relationship of the W-27 antigen and 
spondylitis. 
In the treatment of ankylosing spondylitis, 
radiation therapy was at an early date, found to be 
effective for relief of pain; it's use was given up 
because of a reported high frequency of blood 
dyscrasias following its application. There are still 
some authors who feel that its limited use in patients 
who are having pain in spite of other therapy is of 
distinct benefit and of low risk ( 10). Indomethacin 
and phenylbutazone are the most frequently used 
drugs in the treatment of this disease. An observa-
tion was made recently that a patient with severe 
ankylosing spondylitis who did not respond to the 
above mentioned drugs responded quite well to 
penicillamine therapy ( 11). Steroids are of little 
use in this group of patients. Teaching the patients 
exercises in an attempt to increase diaphragmatic 
breathing is of benefit and exercises may sometimes 
help to maintain the spine in better position. 
It is worth noting that what we have learned 
about this disease in recent years has provided us 
with better methods of establishing the diagnosis and 
prognosis of ankylosing spondylitis. 
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Dr. Irby: For some time the influence of heredi-
ty in ankylosing spondylitis has been fairly well 
established, but the exact mechanism has not been 
understood. Although there has been some evidence 
of familial clustering in peripheral rheumatoid ar-
thritis, studies by Jacox and others in Rochester, 
New York have indicated 25 of 28 siblings of 
monozygotic twins to be discordant for rheumatoid 
arthritis. 
The subject of this discussion is HL-A antigens 
* Presented at Medical Grand Rounds by the Dep;i.rt-
ments of Medicine, Surgery, and Ophthalmology, January 
29, 1974, at the Medical College of Virginia, Richmond. 
**This is Publication No. 73 from the Charles W. 
Thomas Arthritis Fund, Medical College of Virginia. 
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and spondylitis. Since many people do not under-
stand the language of the geneticists, Dr. James 
Pierce will tell us what we need to know about HL-A 
antigens. Questions that often arise include: 1) What 
are HL-A antigens? 2) What is meant by HL-A 27? 
3) How does one go about identifying antigenic 
determinants in tissue typing? 
Later we will try to document how some of 
tqis material applies to many of the rheumatic dis-
eases in which spondylitis is often a feature. In 
conclusion, Dr. Macdonald of the Ophthalmology 
Department will comment on various aspects of 
anterior and posterior uveitis, how the diagnosis is 
made, and what the treatment is of each. Uveitis is 
often a complication of ankylosing spondylitis and 
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Reiter's disease. A representative case involving 
uveitis, arthritis, and the presence of HL-A 27 will 
be reviewed. 
Dr. Edwards: J. C. is a 30-year-old black male 
who was first seen in the Emergency Room of the 
Medical College of Virginia Hospitals on September 
3, 1973. At that time, he complained of pain in his 
back and left wrist. He stated that approximately 
six days earlier, while doing manual labor, he had 
experienced pain and swelling in his neck. The pain 
migrated to his left hip, then between the scapulae, 
and finally into the left wrist. Two weeks prior to 
these complaints, he described a two day illness 
characterized by diarrhea from which he recovered 
with no therapy. Past medical history was significant 
in that he had been treated five years earlier by his 
local physician for a urethral discharge. There is no 
family history of arthritis. 
Physical examination at the onset of his illness 
revealed a T 100.4 °F, P 104 per minute, and BP 
120/74. There was pain in the area of the cervical 
spine when his head was deviated to the right or 
left. In addition there was tenderness to percussion 
over the midthoracjc vertebrae, and a painful, warm, 
swollen, erythematous left wrist. Also noted was a 
small papular lesion on his left heel. An arthro-
centesis of the wrist was unsuccessful. Laboratory 
studies included a hemoglobin 16 gm%, WBC's 
12,600 (78% polys, 13% lymphocytes, 9% mono-
cytes), erythrocyte sedimentation rate (ESR) 15 m111 
per hour (Wintrobe), and a urinalysis with a few 
WBC's and RBC's but no protein, sugar, or acetone. 
Repeat ESR's have been 30-40 mm per hour. 
The following tests were either negative or normal: 
rheumatoid pattern, antinuclear antibody, lupus 
erythematosus cell preparations, antistreptolysin-0 
titer, and urine and blood cultures. An intermediate 
strength PPD was negative at 72 hours. Roentgeno-
graphic studies of his chest, cervical spine, thoracic 
spine, and pelvis were normal. X-rays of the left 
wrist showed soft tissue swelling only. Scrapings for 
the papular lesion on his foot grew Trichophyton 
mentagrophytes. HL-A 27 was found to be present 
using the lymphocyte microcytotoxicity test. 
Because of the concern that the patient was 
suffering from an infectious arthritis, he was treated 
with antibiotics. There was no response to this 
therapy and by mid-September he had, in addition 
to the left wrist, developed painful swelling of his 
right ankle and pain to palpation in his right wrist. 
Anti-inflammatory drugs, including salicylates, Buta-
zolidin®, and gold, did not help. Colchicine was 
likewise ineffective. 
On October 8 he presented with an inflamed 
and swollen right eye. Photophobia was present. An 
ophthalmological consult found a visual acuity of 
20/100 with a raised intraocular pressure in the right 
eye. The left eye was normal. The etiology for this 
nongranulomatous anterior uveitis was unknown but 
felt to be related to the arthritis. Later a posterior 
uveitis was also noted. Complete resolution of the 
uveitis occurred over the ensuing six weeks, while 
the patient was treated with alternate day corticoste-
roids ~n a progressively decreasing dose. The arthritis 
also improved. 
Subsequently the patient has complained of 
left heel pain, yet no objective signs to document the 
development of bony spurs have occurred. There is 
no evidence of active synovitis although he does have 
some limitation of motion of his right ankle and left 
wrist. He denies any further back pain and is no 
longer on any medications. 
Dr. Irby: We are not at all sure of the exact 
nature of this gentleman's illness. When the patient 
was first seen on 'arthritis rounds, the lesions of his 
foet were suggestive of keratoderma blennorrhagica. 
1t' was felt that we were dealing with a case of 
ankylosing spondylitis, possibly Reiter's spondylitis, 
or seronegative rheumatoid arthritis. The latter diag-
nosis was entertained because of the lack of char-
acteristic x-ray findings in the sacroiliac joints or 
syndesmophytes on the margins of the lumbar spines. 
After Trich9phyton mentagrophytes were cultured 
from the patient's foot, the only things we had to 
go on were the clinical picture of arthritis of an 
asymmetrical nature, past history of urethritis, and 
uveitis. Dr. Pierce's laboratory determined HL-A 27 
to be present, so this gives us an opportunity to pre-
sent recent data on the new trend in "spondylitiso-
logy," that of antigenic determinants by tissue typing 
for the histocompatibility antigens. 
Qr. Pierce: In my discussion of histocompatible 
antigens, I want to review several things, such as 
the rapidly changing development of this field, the 
lymphocytotoxicity test-which provides a basis for 
detecting these qntigens, some comments on the 
genetics of inheritance of this system of antigens, the 
nomenclature, a source of constant confusion, and 
finally, the association of disease states with HL-A 
antigens. 
The field of histocompatibility typing began in 
1954, when Dausset, in Paris, discovered that anti-
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bodies were present in the sera of patients who had 
received multiple transfusions, which were directed 
against leukocytes but not erythrocytes. In 1958 
Payne and Rolfe at Stanford University found that 
women who had had multiple pregnancies had simi-
lar antileukocyte antibodies. It was in this same year 
that the first leukocyte antigen was discovered using 
antisera, prepared from these patients, which had 
reacted in common with leukocytes of certain other 
patients. This particular antigen was HL-A 2 which 
is the most frequent HL-A antigen found in Cauca-
sians, being present in over 50% of a random popu-
lation. A significant advance was made in 1964, 
when Terasaki devised a microtest for detecting 
these antigens. The advantage of the microtest over 
the macrotest is that one thousand rather than ten 
tests can be performed on one milliliter of serum. 
A series of international workshops were held in 
the late 1960's. In Torino in 1967, it was first re-
ported that the HL-A antigens were inherited in a 
Mendelian dominant fashion from parent to child. 
The discovery that there are two HL-A loci rela-
tively close together on an autosomal chromosome 
was made in 1970 at the Los Angeles workshop. 
The lymphocyte microcytotoxicity test detects 
surface antigens of lymphocytes. These antigens 
react with specific antibody to form a sensitized 
lymphocyte which then reacts with rabbit comple-
ment. This results in the formation of holes in the 
cell membrane of those lymphocytes with attached 
antibody, allowing a dye to pass into the lymphocytes 
that have been killed. Thus the dark cells seen via 
the inverted phase microscope are dead cells con-
taining dye. In a typical positive well, all the cells 
will be dead. The antisera used for these reactions 
are derived from multiparous women. 
How are these antigens controlled genetically? 
The genes for HL-A antigens are located on an auto-
somal chromosome, with each child receiving one 
chromosome from his mother and one chromosome 
from his father. Two loci controlling a different 
series of antigens are located on each chromosome. 
Therefore, there are two-to-four antigenic possibili-
ties for each offspring. An individual with only two 
HL-A antigens is rare, but this could occur if he 
received an identical pair from his mother and 
father. More common but still unusual and occurring 
in 10% of the population is the presence of only 
three HL-A antigens; the majority of people have 
four HL-A antigens. One should distinguish between 
the incidence of the antigens on a given chromo-
some, or gene frequency, and phenotypic frequency 
which is the incidence actually observed in people. 
The gene frequency of a given antigen is approxi-
mately one half the phenotype frequency. Because 
they are inherited in a Mendelian dominant fashion, 
there are four types of offspring with respect to HL-A 
antigens that a pair of parents may have (Fig. 1). 
Therefore, 25 % of siblings will be HL-A identical. 
Also every child will share one haplotype, which is 
one pair of antigens controlled by the two genes on 
one chromosome with each parent. Therefore, a 
child will share two of the antigens of his father 
and he will usually have two additional antigens from 
his mother which are different from those of his 
father. There is also the chance, which is less than 
1 :4, that a sibling will share no HL-A antigens with 
another sibling. 
What about the nomenclature of these antigens? 
HL-A designates antigens recognized by the World 
Health Organization Committee, which set up cri-
teria for their identification. To be recognized, there 
must be two monospecific antisera which define the 
HL-A antigen and which do not overlap with other 
recognizable HL-A antigens. Tentative recognition 
is given to an antigen, when one monospecific serum 
identifies it and many labs recognize it. This is 
termed the W-classification system and what was 
orginally designated W-27 is now designated HL-A 
27. HL-A antigens have frequently been discovered 
in a number of labs simultaneously, which has led to 
confusion because they are given local designations. 
For example, HL-A 5 has been designated by local 
groups as AO 45, BT 25, 4C, TO 5, DA 5, and 
TE 11. Obviously, it is easier to speak of HL-A 5, 
so order is gradually coming into the field. 
Where do we stand in discovering these anti-
gens? In the first segregate series controlled by one 
genetic locus, the gene frequency of those ten W 
and HL-A antigens already discovered adds up to 
0.978. If all antigens have been discovered, the gene 
frequencies should add up to 1.00. On the second 
segregate series, 15 W and HL-A antigens have been 
discovered, but their gene frequency adds up to only 
0.897, so approximately 10% of this group of HL-A 
antigens remain undiscovered. There is a difference 
in the racial distribution of these antigens. For ex-
ample, HL-A 2 is found in 50% of Caucasians while 
HL-A 9 is found in over 70% of Orientals. One can 
see that a difference of gene frequency of these 
HL-A antigens would provide a basis for difference 
of disease incidence in different racial groups which 
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MOTHER FATHER 
OFFSPRING 
Fig. 1-This illustration depicts a pair of autosomal chromo-
somes from each parent with the two HL-A loci on each 
chromosome and the pattern of inheritance of the HL-A 
antigens; 25% of the siblings will be HL-A identical. 
is relevant to our patient today. The association of 
HL-A 27 with ankylosing spondlylitis and with 
Reiter's syndrome is striking. 
Caution should be introduced, however, about 
the association of an HL-A antigen and a disease 
state. For example, some investigators have found 
a significant association of HL-A 5 with Hodgkin's 
disease while others have found no significant asso-
ciation at all. This is not very surprising, because 
if 21 antigens are studied for association with a 
disease, the chances are that one antigen will be 
significantly associated with the disease by chance if 
the level of significance is P = 0.05. Therefore, a 
correction factor is introduced. The level of signifi-
cance is divided by the number of antigens studied 
in the search for an association. In the case of 21 
antigens, the P value would have to be less than 
0.0024 to have a significant association. 
Two other points should be made about this 
system of antigens-one is that HL-A antigens are 
found on the surface of all somatic or nucleated cells, 
so they are accessible to involvement with diseases; 
secondly, this is the most polymorphic genetic 
system found so far in man, so it lends itself to 
individualization. Even though the incidence of a 
disease may be very small, there is a real possibility 
that it will be found associated with a given HL-A 
antigen. 
Dr. Irby: Although the possible association of 
HL-A antigens with disease susceptibility has been 
investigated for many years, it has been only within 
the past two years that three convincing examples 
have come to light (Table 1). In psoriasis, there is 
an increased disease incidence in first degree rela-
tives and in adult celiac disease, the incidence in 
relatives is six times normal. Patients with rheumatic 
diseases have provided many interesting and signifi-
cant correlations with HL-A antigens (Table 2). 
Earlier studies and subsequent HL-A antigen investi-
gators have demonstrated a striking relationship be-
tween HL-A 27 and ankylosing spondylitis and 
between HL-A 27 and Reiter's syndrome (Tables 
3, 4) . 
Dr. Macdonald: Some years ago the principle 
way of classifying uveitis was on the basis of granu-
lomatous uveitis, in which th.e primary inflam-
matory cell was the epitheloid cell. · In the anterior 
segment of the eye, the exudation was that of a 
heavy proteinaceous material with many synechiae, 
compared to the nongranulomatous variety, in 
which the cell type was nonepitheloid with generally 
a much less severe reaction. In the granulomatous 
types of uveitis, or in iridocyclitis, the actual of-
fending agent was considered to be present. For 
some years, this classification was expounded by 
Dr. Woods at Johns Hopkins University. At present, 
uveitis is generally classified according to where it 
is found in the eye, that is, anterior uveitis (involving 
mainly the iris), both segments (involving the iris, 
ciliary body, and choroid), and those involving only 
the choroid. It is of particular interest that the lead-
ing cause of anterior segment disease is unknown; in 
both segments, the third most common cause is un-
known; and in the posterior or choroidal variety, 
many are unknown. Much work remains in order to 
properly determine the basic etiologies of uveitis. In 
the anterior segment variety, ankylosing spondylitis 
appears to be the third most common cause in this 
series. 
In the literature, a system for studying the 
problem of sympathetic ophthalmia was propounded 
by Elschnig in 1910. He proposed that melanins 
in the uveal pigment of the eye where indeed the 
exciting factors. The studies were carried out by 
complement fixation tests. This has subsequently 
raised the question of the role of melanin in the 
eye. A further interesting question of the relation-
ship of pigmentation in the skin to the Vogt-
Kayanagi-Harada syndrome of vitiligo, poliosis, and 
dysacousis has been raised. 
As we progress through clinical and research ex-
periences, our concepts necessarily change. In 1941 
Dr. Woods at Johns Hopkins reported a study of 
343 cases of uveitis of which 80% were caused 
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TABLE 1 
HL-A ASSOCIATED WITH DISEASE* 
Celiac Disease HL-Al 2t-3 X Normal Stokes, 1972 
HL-A8 3 X Normal Falchuk, 1972 
Ch. Active Hepatitis HL-Al 
HL-A8 3 X Normal Mackay, 1972 
Psoriasis HL-A17 Russell, 1972 
HL-A13 3 X Normal White, 1973 
Ankylosing Spondylitis HL-A27 10 X Normal Schlosstein, 1973 
Brewerton, 1973 
Also some correlation lymphoma, multiple myeloma, SLE, and lymphoblastic leukemia with various phenotypes HL-A. 
* The association of certain HL-A antigens with disease states has proven to be more than a chance correlation. 
by tuberculosis. In 1960 Dr. Woods reported an-
other series including 134 cases of uveitis. In this 
study, only 20% of the cases were caused by 
tuberculosis, whereas 36% were caused by toxo-
plasmosis, 13 % by histoplasmosis and 22 % were 
of unknown etiology. Dr. Kaiser reported .a study 
involving 110 patients with uveitis, and 38% of 
these were caused by histoplasmosis which was the 
largest single group. Much of this is, of course, at-
tributable to the fact that Louisville lies in the Ohio 
Valley which is endemic for Histoplasma capsulatum. 
In our series of over 400 cases of uveitis, 60% have 
been posterior (choroid), 18% anterior, 12% mid-
segment, and 10% involving all segments of the eye. 
Approximately 58% of the cases of anterior uveitis 
had an unknown etiology. There are probably two 
reasons for this. First, there are many types of dis-
eases which will produce a purely anterior uveitis. 
Secondly, ophthalmologists are divided into two 
groups-one group does everything diagnostically; 
the second group treats them all with steroids and 
a large majority get well anyway. Therefore, many 
patients with the anterior uveitis appear to have no 
known cause. In our group with anterior uveitis, there 
were four cases of ulcerative colitis with spondylitis 
( 6 % ) and six cases of Reiter's disease or other 
TABLE 2 
HL-A 27 IN RHEUMATIC DISEASE PATIENTS* 
Condition Presence of HL-A 27 Percentage Source 
Normal 119/ 1456 
Rheumatoid arthritis 10/ 119 
Gout 6/ 66 
Ankylosing spondylitis 35/ 40 
72/ 75 
Reiter's syndrome 25/ 33 
Acute anterior uveitis 26/ 50 
Psoriasis 9/ 156 
6/ 44 
Psoriasis / spondylitis 10/ 14 
8% 
8% 
9% 
88% 
96% 
76% 
52% 
6% 
14% 
71 % 
Russell, 1972 
Brewerton, 1973 
Schlosstein, 1973 
White, 1972 
Schlosstein, 1973 
Schlosstein, 1973 
Schlosstein, 1973 
Brewerton, 1973 
Brewerton, 1973 
Brewerton, 1973 
White, 1972 
Russell, 1972 
Metzger, 1974 
* A compilation of rheumatic diseases and HL-A 27 shows its strong association with ankylosing spondylitis, Reiter's syn-
drome, and psoriatic spondylitis. 
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TABLE 3 
RACIAL ASPECTS OF ANKYLOSING SPONDYLITIS* 
1. Random study McGuire VA H: 26 white, 3 black.-
Toone 1949 
2. Combined VA H study, 301 pts. 10% black.-
Baum 1971 
3. HL-A 27 absent in Black Africans.-Dausset 
4. HL-A 27 only 4% in Black Americans. 
5. HL-A 27 present in 8 of IO Black American spondylitics. 
* The above figures demonstrate the relationship of 
HL-A 27 and ankylosing spondylitis on Black Americans. 
rheumatic diseases ( 8 % ) . Therefore, 14 % of our 
cases of anterior uveitis had some rheumatological 
problem. Ninety-six percent of the cases in our 
series with midsegment disease had no apparent diag-
nosis after workup. Two percent were diagnosed as 
spondylitis. Perhaps, a reason for the small number 
of diagnoses is that ankylosing spondylitis and sacro-
iliitis have, in the past, been overlooked. 
Dr. Irby: So what can we conclude from this 
discussion? 
1. There is an 88-95% incidence of HL-A 27 
antigen in patients with ankylosing spondylitis and 
a 76% incidence in patients with Reiter's disease 
against an 8 % incidence in a controlled Caucasian 
population. 
2. First degree relatives of spondylitics have 
20-30 times the risk of developing spondylitis and 
50% of these will have HL-A 27. 
3. The HL-A 27 antigen may be a useful tool 
in diagnosis or prognosis, particularly in early rheu-
matic disease patients including those with juvenile 
rheumatoid arthritis. 
4. There is a possibility that HL-A 27 may 
predispose a patient to develop Reiter's disease or 
ankylosing spondylitis; however, much work needs 
TABLE4 
HEREDITARY ASPECTS OF ANKYLOSING SPONDYLrns* 
1. 30X more prevalent among relatives of spondylitic 
patients than controls.-Stecher 
2. 22.6X more prevalent in relatives of spondylitics than 
controls.- De Blecourt 
3. W-27 found in 31 / 60 1° relatives.- Brewerton 
4. No blood group association. 
* The hereditary aspects of ankylosing spondylitis 
are clinically apparent as well as genetically significant. 
to be done in this regard to implicate HL-A 27 as 
an etiological factor. 
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Juvenile Rheumatoid Arthritis: Early Diagnosis, 
Management, and Prognosis*** 
JOHN J. CALABRO, M.D., F.A.C.P. 
Chief of Medicine & Director of Rheumatol'ogy, Worcester City 
Hospital; Consultant in Pediatric Rheumatology, New England 
Medical Center, Boston, Massachusetts; Professor of Medicine, 
University of Massachusetts Medical School, Worcester 
Rheumatoid arthritis (RA) is the major chronic 
rheumatic disorder of childhood. It affects as many 
as 250,000 American children and is slightly more 
common in girls than in boys. 
Juvenile rheumatoid arthritis (JRA) is arbi-
trarily defined as RA beginning before the age of 
16. It rarely begins before six months of age, and 
most cases appear between the ages of one and 
three with a second peak at 8-12 years of age. 
Despite the inclination to link RA and JRA 
as identical diseases, one occurring in adults, the 
other in children, there are a number of striking 
differences between the two ( 1-5). In a compara-
tive survey (Table 1), high fever and rheumatoid 
rash occurred far more frequently in children than 
in adults with RA. Another important differenc1.'! is 
that chronic iridocyclitis developed in 8 % of pa-
tients with JRA. Such ocular involvement is .rare in 
adults with RA, if it occurs at all. Of all children 
with JRA, the most susceptible group are those with 
the mildest form of disease-those whose initial on-
set is monarticular and those whose course of disease 
is oligoarticular (pauciarticular); about one in five 
will develop this potentially serious eye inflamma-
tion. A monarticular onset, primarily of a kn•ee, was 
found more often in JRA than in adult RA. This is 
difficult to explain, as is the relative infrequency 
among children of subcutaneous nodules. Fewer 
children (8 % ) had rheumatoid nodules than adults 
* Presented by Dr. Calabro at the 45th Annual 
McGuire Lecture Series, November 9, 1973, at the Medical 
College of Virginia, Richmond . 
**Supported in part by a grant from the Massachusetts 
Chapter of the Arthritis Foundation. 
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(20%) . They occurred, however, in the same areas 
in both groups. Nodules are seen frequently at the 
elbow or may be found in any area of pressure or 
friction, such as the knuckles or at the back of 
the heels . Rheumatoid factor in the serum, as 
observed by either a positive sheep cell agglutina-
tion or latex fixation test, is present in only 10-25% 
of JRA patients, whereas in adults, it is found in 
50-85 % . Failure to appreciate the relative infre-
quency of rheumatoid factor in JRA constitutes one 
of the major pitfalls in early diagnosis. 
EARLY DIAGNOSIS 
Clearly, it is precisely these major differences 
that have created much of the difficulty in the early 
diagnosis of JRA. The problem would be simpler by 
the recognition of three distinct modes of onset. 
These are acute febrile (systemic), polyarticular, and 
monarticular. The frequency, severity, and character 
of initial systemic and articular manifestations help 
to differentiate each. 
An acute febrile or systemic onset is marked by 
systemic manifestations, including high fever, rash, 
generalized lymphadenopathy, splenomegaly, and 
heart involvement. Joint manifestations are variable; 
occasionally only arthralgia is present. In polyarticu-
lar onset, defined as the involvement of more than 
four joints, the arthritis predominates and is fre-
quently generalized and symmetric, similar to RA 
in adults. Systemic manifestations are less prominent 
than in an acute febrile onset and fever is low grade. 
In a monarticular onset, arthritis is confined to a 
single joint, usually a knee; except for iridocyclitis, 
systemic manifestations are either absent or minimal. 
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TABLE 1 
MAJOR DIFFERENCES BETWEEN 1()() CHILDREN AND 
100 ADULTS WITH RHEUMATOID ARTHRITIS 
CONSECUTIVE REFERRALS TO AN ARTHRITIS CLINIC 
Disease Feature 
High Fever 
Rheumatoid Rash 
Chronic Iridocyclitis 
Monarticular Onset 
Subcutaneous Nodules 
Rheumatoid Factor* 
Frequency(%) 
Children Adults 
20 
36 
8 
32 
8 
23 
3 
2 
0 
6 
20 
76 
* By the latex fixation test, titer of 1: 160 or greater. 
Acute Febrile Onset. About 20% of all JRA 
patients present with an acute febrile or systemic 
onset. Recognition is easy when obvious arthritis is 
present in addition to several typical systemic mani-
festations of the disease (Fig. 1 ) . Sometimes, how-
ever, only arthralgia is present and then the differ-
ential diagnosis can be difficult. In those without 
arthritis, the child's appearance may provide the 
first diagnostic clue. These children are irritable, 
listless, anorectic, and losing weight. They often wish 
to be left alone and assume a position of generalized 
flexion. Of the many systemic manifestations, fever 
and rash have the greatest diagnostic value. Both 
may be associated with g~neralized lymphadenopa-
thy (particularly axillary and epitrochlear nodes), 
splenomegaly, hepatomegaly, pericarditis, myocar-
ditis, pneumonitis, and a striking neutrophilic leuko-
cytosis. 
Fever. First, it should be remembered that high 
fever may precede detectable signs of obvious ar-
thritis by weeks, months, or rarely, by years ( 6). 
Rectal temperatures must be taken every four hours 
around the clock in order to disclose the character-
istic quotidian or double quotidian febrile pattern 
(Fig. 2). Typically, there are one or two daily 
temperature peaks above 102°F, occasionally even 
to hyperpyrexic levels (fever to 105°F) ( 6). Diurnal 
ranges are wide, often as much as 8°F or 9°F, so 
that both hyperpyrexia and normal or subnormal 
temperatures occur within the same day. The fever 
usually, but not always, responds to aspirin provided 
large quantities, up to as much as 130 mg/ kg (1 
gr/ lb) daily, are given. If the critical daily quantity 
of aspirin is then reduced, even by as little as 1 50 
83 
mg, the fever recurs promptly ( 6, 7). Eventually 
the fever pattern may become relapsing or even 
periodic ( 6), at which time other typical features 
of JRA become manifest, thereby facilitating a cor-
rect diagnosis. 
Rash. The rheumatoid rash develops in up to 
90% of children with an acute febrile onset (8) 
(Fig. 1). It consists of macular or slightly macu-
lopapular lesions, usually discrete but sometimes 
confluent, that are found on the trunk and extremi-
ties and occasionally about the neck and face. Rarely 
is the eruption pruritic. 
While it may be persistent, more frequently the 
rash tends to be fleeting or evanescent, with migra-
tory macules appearing briefly in the late afternoon 
Fig. 1-The five-year-old girl above with acute febrile onset 
refuses to rotate her head because of cervical pain. Note 
typical anxious appean1nce, axillary prominence resulting 
from lymphadenopathy, symmetrical swelling of hand and 
wrist joints, and macular rash on the chest. (Reprinted by 
permission from Med Clin N Amer 25:567, 1968.) 
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Fig. 2-The characteristic fever pattern of acute febrile 
onset, as shown above in a six-year-old boy, bears con-
siderable diagnostic importance. High fever with its single 
and double <lailrpeaks is suppressed only when the daily 
aspirin dosage is pushed to 110 mg/kg; patient's weight is 
22.7 kg. (Reprinted by permission frqm N Engl I Med 
276: 11, 1967.) 
or early evening, often in conjunction with fever 
spikes. The rash is most florid in areas where the 
skin has been rubbed or subjected to mild trauma, 
such as the light pressure of clothing. This mani-
festation is known as the Kohner phenomenon; it 
may be useful, diagnostically, when parents report 
rash that is not present at the time the child is being 
examined. The typical rash may be elicited by mak-
ing scratch marks on the extremities or along the 
lower abdomen. Within several minutes, linear 
chains of isolated macules will appear that ofte·n 
persist for a day or two (Fig. 3) . 
Clearly, in these patients, it is the invariable 
combination of fever, rash, arthralgia, and other 
systemic features that leads one to an early diag-
nosis of acute febrile JRA. Otherwise, these patients 
are considered to have "fever of unknown origin." 
They will be hospitalized repeatedly, undergo ex-
haustive diagnostic workups, and receive needless 
courses of various antibiotics and even exploratory 
laparotomy. Differe~tial diagnosjs includes eliminat-
ing infection as well as other causes of high fever 
accompanied by rash and joint pain. 
One of the most important disorders to rule out 
is systemic lupus erythematosus (SLE), which is 
unusual in a child younger than five years of age. 
Occasionally, the early skin lesions of SLE may 
resemble the rheumatoid rash, particularly when 
localized in the arms and trunk. Eventually, the 
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rash of SLE takes on its typical butterfly distribution 
over the face and the diagnosis becomes apparent. 
Also, in SLE, the rash is not evanescent, is not 
timed to fever spikes, and does not produce an 
isomorphic response. Further, SLE may be con-
firmed by the presence of oral lesions, renal ab-
normalities, and LE cells. Finally, the absence of 
antinuclear antibodies virtually excludes a diagnosis 
of SLE. 
Connective tissue disorders other than SLE 
must also be excluded. The rashes of Henoch-
Schonlein ( anaphylactoid) purpura, polyarteritis, 
and hypersensitivity angiitis are usually purpuric or 
ecchymotic. Also, each of these disorders is com-
monly associated with hypertension and renal mani-
festations which do not occur in JRA. In the child 
with arthritis and purpura, one must also suspect 
acute leukemia. Signs that suggest leukemia are 
severe anemia, leukopenfa, and destructive lesions 
on x-rays of joints, each of which is distinctly 
unusual in the initial months of JRA (9). 
Polyarticul~r Onset. This mode of onset, with 
arthritis of more than four joints, occurs in about 
half of all JRA patients. Most children appear ill 
and fail to grow. Rash, lymphadenopathy, and 
splenomegaly occur less frequently than in acute 
febrile 0;nset, and the fever is low grade-peaking 
at 101-102°F once or twice daily. Polyarticular 
JRA is recognized easily when the pattern of joint 
involvement i~ generalized and symmetric and in-
volves the hands (Fig. 4); however, when the 
arthritis is c.onfined to large joints, is asymmetric, 
or is migratory, it may be confused with other 
-
Fig. 3-Physician has evoked linear macules (Kobner 
phenomenon) by lightly scratching the patient's abdomen. 
(Reprinted by permission from I Pediat 72: 611, 1968.) 
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Fig. 4-Hartds of a ten-year-old girl with polyarticular onset 
disclosing symmetrical swelling of proximal interphalangeal, 
metacarpophalangeal, and wrist joints. (Reprinted by per-
mission from M ed Clin N Amer 52:567, 1968.) 
rheumatic disorders, particularly rheumatic fever 
(RF). 
The individual macules of RF usually appear 
as open rings with distinct outer edges; there are 
only a few discrete tnacular rings with pale centers 
(Fig. 5) . Typically, the erythema marginatum of 
RF extends centrifugally while the proximal skin 
returns to normal. It rarely lasts for more than a 
week or two, unlike the rash of IRA which persists 
for months. 
Differential diagnosis is aided by close observa-
tion of the fever pattern; quotidian or double quo-
tidian fevers suggest IRA, while remittent or sus-
tained fevers point to RF. Several other features 
help to rule out RF. The most important include 
onset under follcr years of age, cervical involvement, 
a poor mucin clot on synovial fluid analysis, gen-
eralized lymphadenopathy, hepatosplenomegaly in 
the absence of cardiac failure, and arthritis lasting 
for more than 12 weeks. 
Arthritis develops in 3 % of all children who 
are vaccinated against rubella and involves pri-
marily the knees or wrists. Developing within two-
to-eight weeks after vaccination, the arthritis is self-
limited, persisting for a few days to several weeks. 
The most important laboratory clue is a rising 
hemagglutination-inhibition antibody titer. 
Another misdiagnosis is childhood derma-
tomyositis, primarily because the arthritis is so 
similar to that of IRA. lnitiaily, loss of muscle 
strength is minimal and serum muscle enzyme levels 
may be normal while only arthritis predominates. 
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Clues to an early diagnosis of dermatomyositis in-
clude a violaceous periorbital edema (heliotrope 
facies) and the presence of atrophic and scaly 
erythema of the skin over extensor surfaces of joints, 
particuiady the knees, elbows, and hands. 
Monarticular Onset. While the knee is the 
most common site of a monarticular onset (Fig. 
6), the presentation may sometimes occur in other 
joints such as the ankle, elbow, wrist, or even a 
finger joint ( 10). Swelling, stiffness, and pain are 
usually minimal except when the hip is involved. 
Occasionally, painful tendinitis or bursitis, particu-
larly of the heel, may be a presenting symptom. 
Symptoms or attention to the problem may be 
precipitated by trauma, a deceptive characteristic 
and a majo_r pitfall in diagnosis of this mode oJ onset. 
It is ironic that the mildest form of IRA, a 
moharticular onset, which comprises a third of all 
IRA patients, carries with it the serious threat of 
blindness from iridocyclitis ( 11) . What makes this 
ocular manifestation particularly treacherous is that 
it is so often asymptomatic in its evolution, smolder-
ing quietly for weeks or months until failing vision 
alone compels attention. It may be the initiai mani-
festation of IRA or it may occur at any time in the 
course of the disease, eveh after the arthritis has 
remitted. If undetected and untreated, it may lead 
to blindness, primarily from band keratopathy and 
cataracts. While iridocylitis may occur in all chil-
dren with IRA, those with monarticular onset are 
by far the most susceptible. 
Except for the iridocyclitis, one cannot rely 
Fig. 5-In rheumatic fever, most macules appear as open 
rings with distinct outer borders and are larger than those 
observed in IRA. (Reprinted by permission from I Pediat 
72:611, 1968.) 
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Fig. 6-Monarticular onset in a three-year-old girl with 
painless swelling of the right knee. 
on systemic manifestations in this mode of onset. 
Lymphadenopathy and splenomegaly occur infre-
quently, while low-grade quotidian fever and rash 
are only occasionally present. Routine laboratory 
studies, such as the CBC and ESR, are frequently 
normal. 
When one joint is involved, the single best 
test-if the disease is to be differentiated from acute 
infectious arthritis, which may rapidly destroy the 
joint-involves arthrocentesis and evaluating the 
synovial fluid. The first clues are provided by study 
of the gross appearance of the fluid. In JRA, the 
fluid will be clear-to-opalescent, in traumatic ar-
thritis it may be clear-to-blood-tinged, while in in-
fectious arthritis it will be cloudy or turbid. Ex-
amination of a drop of the fresh, uncentrifuged 
fluid under an ordinary microscope may reveal bac-
teria in infectious arthritis. 
Next in order is inspection of the mucin clot. 
A few drops of synovial fluid are added to a small 
beaker containing about 10 ml of 5% acetic acid. 
If the sample is too small to allow this, the acetic 
acid can be drawn into the syringe, and even a slight 
amount of synovial fluid coating the syringe will 
suffice for the test. After allowing a minute for the 
clot to form, the container is shaken. A good clot 
forms a firm, ropy mass that does not fragment when 
shaken. A poor clot quickly flakes and shreds, 
clouding the solution. If the etiology of the ar-
thritis is traumatic, the clot will be good; if rheu-
matoid, it will be good or poor; and if infectious, it 
will be poor. 
The clinical laboratory is required for further 
synovianalysis. In traumatic involvement, the white 
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' cell count will be below 5,000, with fewer than 50% 
neutrophils; in JRA it will be between 15,000 and 
25,000 and the neutrophils will range from 50-90%; 
in infectious arthritis, white cells will soar to counts 
of 50,000-100,000 and more than 90% will be neu-
trophils. Of particular interest are the paired deter-
minations of serum and synovial fluid glucose levels; 
only in traumatic arthritis will these be about the 
same or show a disparity of less than 10 mg% . 
In JRA the difference will generally fall between 
10-25 mg%, while in arthritis of infectious origin, 
it will usually be over 50 mg% 
A negative tuberculin skin test usually rules out 
active tuberculous arthritis. If it is still necessary to 
pursue this possibility, synoviai biopsy will gen-
erally show caseating granulomas and giant cells, 
while in JRA ohe will see nonspecific synovitis with 
hypertrophy, increased vascularity, and round-cell 
infiltration. 
Laboratory and X-Ray Aids. Low-grade anemia 
and an elevated ESR are frequent, except in patients 
with a monarticular onset in whom values for hemo-
globin, hematocrit, and . the ESR are often normal. 
In acute febrile onset, there is a neutrophilic leuko-
cytosis, usually between 20,000 and 30,000 cells, 
but sometimes as high as 50,000 cells/mm3 • A 
less striking leukocytosis occurs in a polyarticular 
onset, while white cell counts are often normal in a 
monarticular onset. Leukopenia rarely occurs in 
JRA; its presence should lead one to suspect leu-
kemia or SLE. 
The latex fixation test is positive in only 10-
25 % of children with JRA. Elevated titers are found 
primarily among children whose disease begins at 
12-16 years of age. Antinuclear antibodies (ANA) 
are present in 10-30% of patients with JRA. Titers, 
however, are much lower than those found in chil-
dren with SLE. Miller (12) has shown that the 
incidence of ANA is highest in girls and in patients 
under six years of age. ANA also seems to correlate 
with the presence of iridocyclitis ( 2). As for serum 
immunoglobulins, persistently elevated levels of IgG, 
IgA, and IgM are generally associated with an in-
creased incidence of hip involvement and a poorer 
functional status. Serum electrophoresis may reveal 
low albumin and elevated ~- and y-globulins. It also 
serves to detect underlying hypogammaglobulinemia. 
Antistreptolysin-0 (ASO) titers, prolonged and 
moderately elevated, occur in about 30% of patients 
with JRA. The titers appear to be nonspecific and 
are also found in childhood tuberculosis, nephrosis, 
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and hepatitis ( 5). They can be inhibited by adding 
albumin to the test procedure, in contrast to specific 
ASO titers, which indicate recent infection with 
Group A ~-hemolytic streptococcus. Intramuscular 
monthly injections of benzathine penicillin over a 
period of 12 months failed to lower titers of ASO in 
six of our patients with JRA, seemingly confirming 
the nonspecific nature of these titers ( 5). 
Early x-ray findings are also nonspecific and 
include soft tissue swelling, early closure of epiphyses, 
and periosteal proliferation ( 5). Osseous erosions 
are only late findings, and their early presence should 
lead one to suspect leukemia or other forms of 
malignancy ( 9). 
COURSE OF DISEASE 
The subsequent course of disease is largely 
determined by the mode of onset ( 1) (Table 2). 
Three patterns of disease course may evolve: poly-
cyclic acute febrile, polyarthritis, and oligoarthritis 
(also known as pauciarticular arthritis). 
Ten of our 20 patients with an acute febrile 
onset have had recurrent flare-ups of systemic fea-
tures, primarily high fever and rash, and little or 
no arthritis-a disease course designated as poly-
cyclic acute febrile. The number of acute febrile 
attacks has varied from one to as many as ten in a 
single year. None of these ten patients has ever 
developed chronic arthritis . The other ten patients 
developed polyarthritis or the simultaneous arthritis 
of more than four joints. This occurred either at 
the onset of disease or only after months-to-years of 
recurrent acute febrile attacks. One girl had periodic 
fever that recurred regularly every three months for 
as long as nine years (from age 3-12) before she 
developed poly arthritis ( 6) . 
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Of the 32 patients with a monarticular onset, 
22 became oligoarthritic, with chronic, often recur-
rent, arthritis of only one-to-four joints; the ten 
remaining children developed polyarthritis. 
Children with a polyarticular onset remained 
polyarthritic. Altogether then, 68 patients ( 48 with 
a polyarticular onset, ten with an acute febrile onset, 
and ten with a monarticular onset) eventually devel-
oped polyarthritis {Table 2). The course of poly-
arthritis took two forms, one characterized by 
exacerbations and remissions (58 patients), the 
other by an unremitting and progressively downhill 
course (13 patients)-resulting in marked joint 
deformities and an enhanced susceptibility to sec-
ondary amyloidosis. Amyloidosis should be suspected 
when there is progressive hepatosplenomegaly or 
when proteinuria develops that is unrelated to gold 
therapy. 
MANAGEMENT 
The aim of treatment is to provide a setting 
that will give the young patient a reasonably normal 
childhood. Management must include an active home 
program and regular follow-up care, because therapy 
may have to be changed at any time during the long 
course of the disease ( 13). 
From the outset, the physician must recognize 
that he can only initiate and supervise therapy. The 
actual treatment will be given in the home, and the 
results will depend on establishing a working rela-
tionship with the parents. Therefore, the physician 
must educate and motivate the parents. He must 
teach them all about their child's disease-what they 
must do, and what they may expect. This is clearly 
the best way to reassure the parents and to allay 
their anxieties. 
TABLE2 
THE ONSET, COURSE, AND OUTCOME OF 100 PATIENTS WITH JUVENILE RHEUMATOID ARTHRITIS OBSERVED FOR 15 YEARS* 
Modes of Onset 
Acute Febrile 
Polyarticular 
Monarticular 
% Course of Disease 
20~ Polycyclic AcFeb 
48 Polyarthritis 
32 Oligoarthritis 
% 
10 
68 
22 
Outcome(%) After 15 Years 
Still Active 
28t 
7 
Classes 
III-IV 
0 
13t 
0 
Itidocyclitis 
0 
2 
6:j: 
* During these 15 years, 88 of-our 100 children were maintained only on aspirin. Only four children have received oral steroids 
for more than one year, two because of protracted iridocyclitis; eight are currently on gold therapy. 
t Including three deaths, one from postsurgical sepsis, one from secondary amyloidosis, and one of suicide. 
i Two children are blind in one eye. 
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Drug Therapy. Salicylates. While physical thera-
py is the most important part of home care, it can 
only be made possible by the use of antirheumatic 
drugs that reduce joint inflammation and increase 
mobility. Whatever the mode of onset, aspirin, in 
individualized doses, is the drug of choice. Active 
disease can be suppressed in most children by four-
to-six daily doses, totaling 90-130 mg/ kg (2/ 3-1 
gr/ lb) daily. Acute febrile disease requires the more 
frequent and higher doses. 
Early signs of chronic salicylate intoxication 
can easily be overlooked. Parents must be instructed 
to watch for lethargy and episodic hyperpnea, changes 
that are especially important in a child who is too 
young to complain of tinnitus. When these symptoms 
occur, aspirin should be stopped for 24 hours, and 
then reinstituted at slightly lower doses. 
Adrenocorticosteroids. These drugs are admin-
istered in heart failure due to myocarditis as well as 
in pericarditis, vasculitis, and protracted iridocyclitis. 
For short periods, they may also be given in acute 
febrile disease or to patients who either do not 
tolerate or who fail to respond to aspirin. Intra-
articular injections of steroid may also prove bene-
ficial, especially when one or two joints are so 
seriously inflamed that exercise and other rehabilita-
tive efforts are being compromised. 
Chrysotherapy. Children with polyarthritis who 
respond poorly to aspirin should be given a trial of 
gold therapy; however, only physicians experienced 
in its use and potentially serious side effects should 
prescribe and administer gold. Gold salts are in-
jected intramuscularly at weekly intervals in a dose 
of 0.5-1 mg/ kg. Complications are more frequent 
during the early months of therapy and in children 
less than six years old. Renal and hematopoietic 
side effects are potentially fatal, and it is, therefore, 
necessary to monitor the patients with weekly blood 
and urine tests. These tests must be evaluated before 
each injection. 
Other Drugs. The antimalarial drugs are not 
recommended for routine use in children. Chloro-
quine is especially dangerous; the accidental inges-
tion of as little as one gram (four tablets) may cause 
rapid cardiorespiratory arrest. Serious toxic effects 
to phenylbutazone and oxyphenbutazone include 
hepatitis, thrombocytopenia, and agranulocytosis, 
which seem to occur more frequently in children 
than adults. For this reason, these drugs are cur-
rently contraindicated in children 14 years of age 
or under. So, too, is indomethacin. The place of 
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immunosuppressive or cytotoxic agents has not yet 
been evaluated in JRA. 
Eye Care. Susceptibility to iridocyclitis is en-
hanced in all patients with JRA. The recognition 
and therapy of iridocyclitis should be entrusted to 
an ophthalmologist. In those with minimal arthritis, 
the most susceptible group, slit-lamp examinations 
are required every three months, even if the arthritis 
is in remission. Patients who have had previous 
iridocyclitis should be examined on a monthly basis. 
All other JRA patients should be examined regularly 
by slit lamp at six-month intervals. Ophthalmologic 
screening should be routine until patients reach 
adulthood, at which time attacks tend to become 
acute and routine screening for silent iridocyclitis 
is no longer necessary. 
Supportive Care. Appropriate rest, splinting, 
and exercise are fundamental to the prevention and 
:;orrection of deformity. An increase in the hours of 
sleep at night and a nap during the day facilitate the 
resolution of synovial inflammation. Complete bed 
rest must be avoided, however, since this may cause 
undue flexion contractures and muscle atrophy. 
Bivalved splints, made of plaster of paris or of 
plastic, are used to rest inflamed joints or to correct 
deformities . Traction, sandbags, or other means of 
keeping joints in proper alignment may be used in 
place of resting splints. For sustained deformities-a 
flexion contracture of a knee, for example-serial 
splinting may be useful. New bivalved splints are 
applied every one-to-two weeks as the range of 
motion improves. Splints may be removed daily to 
permit prescribed exercises and then replaced. 
A physiatrist or physical therapist must teach 
the patient or parents a program of regular daily 
exercises that can be performed in the home. Daily 
activities, in addition to formal exercise, should be 
those that maintain strength and move joints pri-
marily through motions of extension. Games and 
sports can help to achieve these goals, but those 
which involve sharp impact to the joints, such as 
basketball or football, must be avoided. Swimming 
is an excellent sport, since it promotes mainly 
extension-type movement and has the added ad-
vantage of the positive buoyancy of water. Keeping 
the child in school also assures that mental activities 
are maintained. Provisions must be made, however, 
to allow the patient more freedom than other 
children. 
Surgery. Established deformities can be success-
fully corrected by a variety of procedures, even in 
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the presence of active disease. Early synovectomy, 
or the removal of granulation tissue early enough to 
prevent erosion of cartilage and bone, however, is an 
area of current controversy. The correct timing of 
the procedure and the proper selection of patients 
are the issues at the moment. Generally, children six 
years or younger are poor surgical risks because of 
their inability to cooperate fully with important post-
operative measures. 
PROGNOSIS 
Generally, the prognosis for children is quite 
favorable ( 1, 2). Of our 100 patients now observed 
prospectively for 15 years, 64 are in remission 
(Table 2 )-they are not taking any drugs and have 
no evidence of active articular or systemic disease. 
All 64 patients are in functional classes I and II 
and therefore capable of all ordinary activity. 
Active disease was present in 36 patients, in-
cluding the three who died. Of the 36, 28 have had 
a course of polyarthritis. Only one of ten patients 
with a polycyclic acute febrile course and seven of 
22 with oligoarthritis continue to be active, affirming 
the benign nature of these two patterns of disease 
course. 
Only 13 patients are in the unfavorable Ameri-
can Rheumatism Association functional classes III 
and IV and are capable of little or no activity. Each 
has had a course of unremitting polyarthritis and ten 
have had progressive hip involvement. Three of 
these patients died, one of staphylococcal bacteremia 
following knee synovectomy, one from secondary 
amyloidosis, and the third of suicide. Permanent 
stunting of growth occurred in seven of these 13 
patients, six of whom also had pronounced micro-
gnathia and progressive cervical involvement. 
One of our most striking observations is that 
chronic iridocyclitis appeared and recurred primarily 
in patients with the least amount of joint involvement 
(Table 2). Of the eight patients with iridocyclitis, 
six had oligoarthritis, two of whom lost vision in one 
eye. Iridocyclitis subsequently recurred in three of 
these six children and in two when their arthritis 
had been in remission for as long as four years. 
CONCLUSIONS 
Varying degrees of systemic and articular in-
volvement characterize the three modes of onset 
observed in JRA. Systemic features, notably high 
fever and rash, characterize an acute febrile onset 
which may be observed weeks, months, and even 
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years before objective arthritis develops. In poly-
articular onset, the arthritis predominates and is 
frequently generalized and symmetric, similar to 
adult RA. Monarticular onset, with arthritis con-
fined to a single joint, is the mildest form; it poses, 
nevertheless, the major threat of potential blindness 
from chronic iridocyclitis. 
Treating the patient with JRA is a long-range 
collaborative effort, the success of which will largely 
depend on early diagnosis along with home care 
and parental cooperation. For all modes of onset, 
and subsequently during active arthritis, aspirin 
continues to be the drug of choice. Management must 
include regular follow-up and comprehensive care 
to prevent joint deformity and blindness due to 
asymptomatic iridocyclitis. The prognosis is gen-
erally favorable, as gleaned from our 15-year pro-
spective study of 100 patients, and this allows us to 
discard old fears that JRA is inevitably unremitting 
and largely intractable to treatment. 
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A Review of Som·e Aspects of L-Forms and 
Gonococci* ** 
CHARLES L. COOKE, M.D., BERNARD GERMAIN, M.D., BONNIE BALDUCCI, M.S., 
HARRY P. DAL TON, Ph.D. 
From the Division of Connective Tissue Diseases, Medical College of 
Virginia, Health Sciences Division of Virginia Commonwealth 
University, Richmond 
Systemic manifestations of gonococcal disease, 
such as arthritis, are often sterile on the usual 
culture methods used to grow gonococci. Allergic 
mechanisms have been invoked to explain this but 
with little evidence to support the concept (1-3). 
With the report by Holmes et al. ( 4), that L-forms 
of gonococci were isolated from joint fluid of a 
patient with gonococcal arthritis, we decided to 
investigate the possible role of L-forms in gonococcal 
disease. 
Biology of L-Forms of Bacteria. Kleineberger in 
1935 (5) first described L-form formation in 
Streptobacillus moni.liformis organisms. L-forms of 
organisms are also known as protoplasts, variants, 
or spheroplasts. In protoplast formation, organisms 
lose their normal rigid cell walls and are able to 
survive, reproduce, and revert to the normal cell 
wall possessing parent forms. These features dis-
tinguish L-forms of bacteria from mycoplasmas, 
which never have rigid cell walls. Media, made 
hypertonic with sucrose, sodium chloride, or other 
things, are necessary to grow L-forms without lysing 
the cells and destroying them. Lacking cell walls, 
L-forms do not show up on the usual Gram's stain. 
Numerous species of bacteria, including E. coli, 
staphylococci, enterococci, and certain fungi are 
capable of L-form formation ( 6). This phenomenon 
can be induced by the presence in hypertonic media 
of certain amino acids, some antibiotics, lysosomal 
* Presented at the 45th Annual McGuire Lecture Series, 
November 9, 1973, at the Medical College of Virginia, 
Richmond. 
**This is publication No. 75 from the Charles W. 
Thomas Arthritis Fund. 
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enzymes, or the combination of complement and 
antibodies. 
The question of pathogenicity of L-forms is 
far from answered. Work by Gutman et al. (7) 
clearly demonstrated that protoplast formation is 
a mechanism whereby organisms can persist in the 
urinary tract despite antibiotic therapy. Antibiotic 
therapy with ampicillin caused Proteus mirabilis 
organisms in their patient to revert to L-forms which 
are quite resistant to ampicillin. With cessation of 
therapy, the organism can revert to the parent form 
possessing a cell wall-thus assuring persistence of 
the infection. 
Seven L-form media, the formulae of which 
have previously been published ( 8), were simul-
taneously inoculated with a recently isolated strain 
of Neisseria gonorrheae. In order to increase L-form 
colony recovery, one of the four cell wall antibiotics 
( ampicillin, benzathine penicillin, methicillin, or po-
tassium penicillin G) was incorporated into the 
seven media. This comparison was repeated with 
21 strains of gonorrheae and with each of the four 
antibiotics to give a total of 588 comparisons. There 
was a total of 187 cultures which demonstrate the 
presence of L-form cultures; however, three media 
accounted for 62% of the positive cultures. These 
three high recovery media were used, without anti-
biotics, in conjunction with chocolate and Thayer-
Martin media, in two clinical studies designed to 
isolate L-forms or coccal forms of gonorrheae. 
In the initial clinical study we cultured on high 
recovery media material from the urethral exudate 
of twelve patients with acute urethritis. None of 
these grew L-forms. In the second clinical study we 
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cultured JOlllt fluid from 17 patients with acute 
arthritis . Twelve of these had clinical features sug-
gestive of gonococcal arthritis; again, no L-forms 
were grown. Five patients with either gout or osteo-
arthritis grew no organisms. Thus we were unable to 
demonstrate a role for L-forms in the pathogenesis 
of gonococcal disease. 
That L-forms are present in some patients and 
stages of infection cannot be denied on the basis of 
Holmes' work; neither can it be denied on the basis 
of the work of Orcinnikov and Delektorskij (9) 
who have demonstrated, by use of electron micros-
copy, the presence of wall-less gonococcal cells in 
prostatic secretions. The possibility also exists, how-
ever, that gonococcal L-forms are transitory-that 
is, they are injured cells on the way to death and 
do not significantly enter into the pathogenic process. 
This possibility is reinforced by the present study 
and also by that of Orcinnikov and Delektorskij, 
because they were able to demonstrate gonococcal 
L-forms using electron microscopy; but in no case 
were they able to grow the organism. 
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Summary of Papers Presented at the 45th Annual 
McGuire Lecture Series* ** 
ROBERT IRBY, M.D., PROGRAM CHAIRMAN 
Professor of Medicine, Division of Connective Tissue Diseases, 
Medical College of Virginia, Health Sciences Division of 
Virginia Commonwealth University, Richmond 
It is the purpose of this presentation to quickly 
review some of the important points of the papers 
which were presented at the 45th Annual McGuire 
Lecture Series on the subject of immunology and 
rheumatic diseases. The first paper was presented 
by Dr. Mullinax who gave a background on the 
historical aspects of immunology, beginning with 
Jenner and cowpox immunology and immunity to 
attenuated smallpox demonstrated in milk maids, 
continuing through the contributions of Pasteur, 
von Pirquet (on serum sickness), Bence Jones, 
and Hargraves (with the LE cell in 1948), down 
to modern immunology with antibody structure by 
Dr. Porter in 1960. Dr. Mullinax also briefly alluded 
to light chains and heavy chains, suggesting that 
there were two domains in light chains and four 
domains in heavy chains. (This subject was later 
presented in more detail by Dr. Franklin.) He then 
turned to the B cells and T cells, indicating ·that 
B cells were producers of humoral or circulating anti-
bodies whereas the T cells dealt more with cellular 
immunity and delayed hypersensitivity. He also in-
troduced the five types of immunoglobulins known 
at this time. 
Dr. Horwitz described the "three R's" of de-
layed hypersensitivity. The three R's included recog-
nition, response, and reaction, all of which con-
tributed to the afferent as well as the efferent limb 
of the inflammatory reaction. He demonstrated 
scanning electron microscopic pictures of B lympho-
cytes showing rough contour in contrast to the T 
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lymphocytes which had a smooth contour. He then 
mentioned how these reactions were studied through 
skin windows and demonstrated the rosette tech-
nique with lymphocytes and sheep red cells. The 
disorders of recognition were due to absence of T 
lymphocytes. The diseases associated with serum in-
hibition of the lymphocyte function included various 
hematologic disorders and solid tumors, SLE, TB, 
multiple sclerosis, hepatitis, and leprosy. He also 
stated that as far as the immunosuppressant effects 
of drugs on delayed hypersensitivity are concerned, 
cyclophosphamide had the greatest effect on the B 
lymphocytes whereas 6-MP had the greatest effect 
on the T lymphocytes. 
Dr. Moncure talked about laboratory studies 
in the diagnosis of rheumatic diseases, covering the 
third component of complement and ANA titers. 
He described the various immunofluorescent patterns 
which we see in SLE-peripheral, homogenous, 
and nucleolar. About one-half of the patients with 
nucleolar patterns are found to have systemic scle-
rosis. He stated that perhaps the ANA test was 
more sensitive and less specific than the LE test. 
Patients with juvenile rheumatoid arthritis were not 
likely to develop positive rheumatoid factor tests . 
Dr. Davis discussed immune complex reactions 
of systemic lupus erythematosus. He demonstrated 
very well the work of Dixon in the original study 
with iodinated bovine serum albumin and anti-BSA 
antibody formation, with incorporation of comple-
ment and deposition of complexes in the skin, joints, 
and heart in complex disease. He also mentioned 
the fact that rheumatoid factor added to the system 
would further precipitate the DNA-anti-DNA in 
the system, possibly indicating the role of rheu-
matoid factor in rheumatoid arthritis. 
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Dr. Rothfield's subject was the diagnosis and 
treatment of lupus nephritis. She mentioned the 
various types of kidney lesions-focal, diffuse, and 
membranous-in SLE nephritis and demonstrated 
beautifully the immunofluorescent pattern in the 
various types. She pointed out that in order to 
study the uptake in the immunofluorescent pattern 
in patients who have membranous glomerulone-
phritis, an H & E section present with the immuno-
fluorescent sample is needed. She also stated ·that 
CNS lupus may have complexes deposited in the 
cord. Elaborating further, Dr. Rothfield indicated 
that focal glomerulonephritis patients do not die of 
renal insufficiency and that hematuria correlated 
closely with activity in SLE. Patients with the dif-
fuse lesions are nearly all dead within three years 
even with prednisone and they have the worst prog-
nosis. All membranous glomerulonephritis patients 
have nephrotic syndrome and in children, particu-
larly, SLE presents a poor prognosis. Dr. Roth-
field's general measures for treatment included rest, 
avoiding sun lig~t and immunizations, proper 
handling of infecti6ns, and avoiding pregnancy. The 
treatment for focal nephritis is steroids. Patients 
with membranous , nephritis do not do well on 
steroids or immunosuppressive drugs such as 
Cytoxan® since this is not an inflammatory lesion 
and, therefore, would not necessarily respond readily 
to them. Diffuse SLE nephritis, of course, is the in-
dication for the use of combined steroid and im-
munosuppressive therapy. The question is still un-
certain as to whether or not this really will prolong 
the life of patients with systemic lupus. 
Next, Dr. Ziff delivered the first McGuire Lec-
ture entitled, "The Rheumatoid Synovium." He 
pointed out that in the rheumatoid synovium there is 
a proliferation of the lining layer as well as an in-
filtration of the deep layer. The two types of cells 
which are present are phagocytic and synthetic cells, 
the synthetic cells being the fluid producers. He also 
mentioned the presence of the IgG rheumatoid fac-
tor complexes which are present in the deep layer. 
The formation of inclusion bodies with release of 
lysosomal enzymes is thought to be one of the 
methods of inflammatory reaction. The second half 
of the cycle is the activation of complement com-
plexes which cause chemotaxis. The A and B cells 
are the cells in the lining layer, whereas the deep 
layer contains deposits of IgG and IgM and deposits 
of C3 and C4. This IgG site was indicated as the 
site at which rheumatoid factor is formed. 
IRBY: SUMMARY 
Dr. Owen spoke about synovial fluid. He dem-
onstrated the value of examining a regular wet-prep 
and how one can use compensated polarized 
microscopy to differentiate between calcium pyro-
phosphate crystals and gouty crystals. He stated 
that rheumatoid arthritis (RA) cells are not diag-
nostic of rheumatoid disease but can be quite helpful 
in diagnosis if present in the synovial fluid. He also 
discussed the benefit of determining synovial fluid 
complement since when elevated, .it is an aid in 
differentiating Reiter's syndrome from some of the 
other nonspecific cases of inflammatory synovitis. 
Dr. O'Brien followed with a discussion of some 
of the newer nonsteroidal anti-inflammatory drugs 
used in the treatment of rheumatoid arthritis. He 
began by covering the use of aspirin, gold, and 
antimalarials. He pointed out that the problem in 
drug evaluation is that in early studies, particularly 
with indomethacin, investigators were not geared 
up for control studies. We now feel that indo-
methacin for treatment of rheumatoid arthritis is 
not as good as it was at first thought to be. It may 
be superior to placebo; perhaps, it is equal to small 
doses of phenylbutazone. Dr. O'Brien maintained 
that a patient should not be placed on a drug study 
unless he was not doing well. He mentioned newer 
preparations under investigation, some of which 
have been discontinued because of fatal hepatitis. 
Some promise was shown for the proprionic acid 
derivatives, one of which was fenoprofen calcium 
which is less :toxic than aspirin. In a dose of 400 
mg per day, it is about as effective as 15 aspirin 
tablets daily without the side effects of aspirin. We 
have been using this drug on an experimental basis 
here for over a year now and find that it is very 
effective in the management of some cases of 
rheumatoid arthritis. He mentioned some of the 
other indole derivatives, all of which have some-
what the same effect as lndocin®. 
On the second day of ·the symposium, Dr. 
Buckley spoke on the immuncxleficiency diseases. 
She discussed agammaglobulinemia associated with 
arthritis and reported four patients who had hypo-
gammaglobulinemia. The B cells in these cases are 
not able to produce lgG. She also discussed selec-
tive lgA deficiency. Some of these patients have 
ataxia telangiectasia and chronic, recurring infec-
tions, atopic disease, autoimmune disease, and 
diarrhea. The lymph node biopsies from these pa-
tients may show two different types of findings. 
The B cell deficits will show absence of the cortical 
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follicles .in the lymph node, whereas the T cell 
deficits may show some derangement in the medulla 
of the lymph node. She demonstrated some of the 
ways of marking B and T cells by using the rosette 
method which Dr. Ziff discussed later. The two 
types of agammaglobulinemia were contrasted-the 
Bruton type and ,the other type in which the plasma 
cells did not secrete lgA. Patients with B cell deficits 
can live to adulthood but severe T cell deficit pa-
tients die within two years. This is the "Swiss" type 
of agammaglobulinemia. Bone marrow ·transplanta-
tion from a histocompatible sibling may be a life-
saver and about half of those done have been 
successful. For treatment of B cell deficiency, she 
indicated that the simple use of y-globulin is not 
sufficient, that all five classes of immunoglobulin 
need to be replaced by plasma infusions in lieu of 
injection of y-globulin. Dr. Buckley encouraged the 
use of the "buddy system," siblings or friends who 
live in the same home who are HAA negative. 
Dr. Calabro talked about juvenile rheumatoid 
arthritis, early diagnosis, management, and prog-
nosis. He indicated that juvenile rheumatoid arthritis 
usually came on before the 16th year of life and 
pointed out the differences in the features of juvenile 
rheumatoid arthritis and adult rheumatoid arthritis. 
The major difference is that adults have rheumatoid 
factor present and juveniles, as a rule, do not. Also, 
subcutaneous nodules are more common in adults 
than in children and the fever, rash, and iritis are 
usually not present in adult rheumatoid arthritis but 
are present in juveniles. Dr. Calabro described three 
modes of onset : the acute febrile or Still's type, the 
polyarticular, where four or more joints are in-
volved, and the monarticular, where only one joint 
is involved. Patients of the third group are more 
likely to develop chronic iridocyclitis and they get 
into real difficulty as time goes on. The fever is a 
"double" type of fever whereby the temperature at 
sometime during the day may go down to below 
normal. The fever usually responds very promptly 
to aspirin in large doses. The Kobner phenomenon, 
similar to an urticaria! type of reaction, is one in 
which ,the rash can be brought out with a simple 
stroke on the skin. Although quite helpful, this is 
not specific for the rash of juvenile rheumatoid 
arthritis in that other types of rashes may behave 
similarly. The laboratory aids here are the presence 
of anemia, elevated ESR and lymphocytosis. These 
children frequently have positive ANA titer, may 
have positive ASO titer, and the x-ray will frequently 
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show periostitis. In Dr. Calabro's 15-year follow-up, 
many of the monarticular patients went on to de-
velop polyarticular states and the same was true for 
patients with the oligoarticular type. Treatment con-
sisted of aspirin, gold salts, and steroids, with 
steroids particularly advisable in the acute febrile 
Still's patient where there was pericardia! or eye 
involvement. 
Dr. Baum discussed ankylosing spondylitis which 
he said was not a variant of rheumatoid arthritis. 
He stated criteria for diagnosis of ankylosing spondy-
litis and demonstrated certain feaures in the ex-
amination of a patient with ankylosing spondylitis. 
A very interesting x-ray finding, the syndesmophyte, 
was discussed-vertical syndesmophytes in spondy-
litis versus horizontal osteophytes in osteoarthritis. 
The various associated complications-aortitis, iritis, 
heart block, amyloidosis, subluxation, and pul-
monary fibrosis-were discussed. The variants of 
ankylosing spondylitis-psoriatic, chronic ulcerative 
colitis, Whipple's, and Reiter's spondylitis-were 
discussed. The work that has been done, particularly 
by Dr. Schlosstein and Dr. Terasaki at Los Angeles 
on the transplant antigen W-27 locus, was sum-
marized. Eighty-eight percent of patients with 
ankylosing spondylitis demonstrated this antigen as 
opposed to :an 8 % incidence in a random popula-
tion. This certainly points to some genetic aspect in 
ankylosing spondylitis. It may also have something 
to do with the prognostic significance, particularly in 
children, if a patient possesses a W-27 antigen locus. 
Dr. Franklin, "Mr. Immunoglobulin," talked 
about the G, A, M, D, and E myelomas and de-
scribed the structure of the immunoglobulin molecule 
with the Fab fraction or the antigen binding site and 
the constant fraction (Fe) of the immunoglobulin. 
He listed the various H-chains and L-chains of IgG, 
A, M, D, and E and talked about the I-chain. By 
the time a diagnosis of multiple myeloma is made, 
the chances are that the patient has had the disease 
some 15 years prior to the time that bone lesions 
appear. The bone pain is usually the factor which 
brings the patient to the doctor. The other disorders, 
macroglobulinemia, H-chain disease, and the benign 
monoclonal gammopathy were discussed. Benign 
monoclonal gammopathy is present in about 3% 
of patients over 60 years of age. There are about 
35 cases of yH-chain, about 50 cases of aH-chain, 
and only 7 cases of µH-chain disease reported. These 
are very rare, but they have certain characteristics of 
yH-chain myeloma and may simulate lymphoma. 
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Palatal and uvula swelling are ·two things which 
sometimes aid in making the diagnosis. Rarely do 
these patients have bone lesions and recurrent infec-
tion is usually the reason for seeking medical atten-
tion. These patients have a characteristic electro-
phoretic pattern. Patients with aH-chain disease 
usually have malignant lymphoma of the intestine 
and malabsorption. The aH-chain is produced in 
the plasma cells lining the intestine and may or may 
not be malignant. Of seven elderly patients with 
µ-chain disease, all had chronic lymphocytic leu-
kemia. Lymphadenopathy is usually absent and these 
patients have hepatosplenomegaly and a high inci-
dence of Bence Jones protein and K-light chains in 
the urine. The finding that is very helpful in diag-
nosis of µ-chain is the presence of a large vacuolated 
plasma cell which can be found in the bone marrow. 
The bad effects caused by these proteins are 
the hyperviscosity syndrome, cryoglobulinemia and 
Bence Jones protein, the latter of which damages 
the kidney. They have bleeding and clotting dis-
orders, infections, hemolytic anemias, and amy-
loidosis. Dr. Glenner and his group at NIH now 
have indicated that light chain fragments are present 
in amyloidosis. 
Dr. Waller discussed the serum agglutinators 
and indicated that rheumatoid factors were IgM, 
whereas the serum agglutinators were antiglobulin 
antibodies or IgG which are a normal constituent of 
serum. These are closely associated with suppurative 
infection, particularly gram-positive organisms. The 
hidden sites on the Fab fragment are responsible 
for the formation of the serum agglutinators after 
papain or pepsin digestion. There are about 14.9% 
positive serum agglutinators in a hospital population 
as opposed to 0.5% in our arthritis clinic. Large 
abscesses usually have positive tests; subacute bac-
terial endocarditis may have positive tests for serum 
agglutinators. 
IRBY: SUMMARY 
Dr. Ziff presented the second McGuire Lecture 
on "Viruses and the Connective Tissue Diseases." 
Again he stated that T cell lymphoblasts in the pres-
ence of antigen can convert B cells into plasma cells 
to produce serum antibody and that virus infections 
would diminish T cell formation. Dr. Ziff discussed 
further the concept of T cell helper and T cell sup-
pressor substances in which he indicated that viruses 
might be an enhancing mechanism to stimulate the 
B cells ·to produce autoantibody. 
Dr. Bisno spoke on the subject of acute rheu-
matic fever and glomerulonephritis with strepto-
coccal antigen. He did mention the fact that ASO is 
frequently elevated in throat infections and not 
necessarily elevated in pyoderma. The sequelae of 
the throat infections are more likely to produce 
acute rheumatic fever than acute glomerulonephritis, 
whereas the sequelae of the skin infections are more 
likely to produce acute glomerulonephritis. Dr. Bisno 
briefly discussed the streptozon test, on which he 
and his associates are now working, which may be 
very helpful in the diagnosis of streptococcal infec-
tion and sequelae. 
Dr. Blaylock's lecture included a discussion of 
urticaria, hives, eczematous dermatitis and rheuma-
toid lesions. IgE is the immunoglobulin which is 
present in patients with urticaria, hay fever, asthma, 
and penicillin allergy. He noted ·that pemphigus 
vulgaris has 7S yG which is usually laid down be-
tween the cells and around the keratinocytes. Gamma 
G globulins will vary in pemphigus vulgaris, whereas 
in bullous pemphigus the serum globulins usually 
stay the same. IgG is usually deposited on the base-
ment membrane similar to that in SLE. Dermatitis 
herpetiformis produces IgA on the basement mem-
brane. 
Dr. Cooke discussed methods of early diagnosis 
of gonococcal arthritis and the absolute necessity of 
instituting prompt treatment. 
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how big a dose will now 
bring relie£if it is a narcotic? 
"Tolerance is an ever-present hazard to continued 
use of narcotics .... The very f irst dose diminishes the 
effects of subsequent doses." 1 And, as increasing 
amounts of narcotics are required to control pain, dis-
tressing adverse effects- lethargy, hypotension, con-
stipation , etc.-can needlessly debilitate the pat ient. 
1.Sadove, M. S.: A look at narcotic and non-narcot ic analgesics, Postgrad. 
Med. 49:102, June 1971. 
how big a dose will now 
bring relief if it is Talwin? 
Chances are, the same 50 mg. Talwin Tablet you 
prescribe originally wil l continue to provide good pain 
relief. Ta lwin can be compared to codeine in anal-
gesic efficacy: one 50 mg. tablet appears equivalent 
in ana lgesic effect to 60 mg. (1 gr.) of codeine. How-
ever, pat ients receiving Ta lwin Tablets for prolonged 
periods face fewer of the consequences you've come 
to expect with narcotics. There should be fewer 
"adverse effects" on her way of life. 
Tolerance rare: Tolerance to the analgesic effect of 
Ta lwin Tablets is rare. 
Dependence rare: During three years of wide clinical use, there 
have been a few reports of dependence and of withdrawal symp-
toms with orally administered Ta/win. Patients wi th a history 
of drug dependence should be under close supervision while 
receiving Ta/win orally. 
In prescribing Ta/win for chronic use, the physician should 
take precautions to avoid increases in dose by the patient and 
to prevent the use of the drug in anticipation of pain rather 
than for the relief of pain.* 
Generally well tolerated by most patients*: Infrequently causes 
decrease in blood pressure or tachycardia; rarely causes respi-
ratory depression or urinary retention; seldom causes diarrhea 
or constipation. Acute, t ransient CNS effects, described in 
product information on fo llowing page, have occurred in rare 
instances fo llowing the use of Talwin Tablets. If dizziness, 
lightheadedness, nausea or vomit ing are encountered, these 
effects may decrease or disappear after the f irst few doses. 
•see important product information on next page for adverse reactions, patient 
selection, prescribing and precautionary recommendat ions. 
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Analgesic for Oral Use 
Indication: For the relief of moderate to severe pain. 
Contraindication: Talwin shou ld not be administered to patients 
who are hypersensitive to it. 
Warnings: Drug Dependence. There have been instances of psy-
chological and physical dependence on parenteral Ta/win in pa-
tients with a history of drug abuse and, rarely, in patients without 
such a history. Abrupt discontinuance following the extended use 
of parenteral Ta/win has resulted in withdrawal symptoms. There 
have been a few reports of dependence and of withdrawal symp-
toms with orally administered Ta/win. Patients with a history of 
drug dependence should be under close supervision while receiv-
ing Ta/win orally . 
In prescribing Ta/win for chronic use, the physician should take 
precautions to avoid increases in dose by the patient and to pre-
vent the use of the drug in anticipation of pain rather than for the 
relief of pain. 
Head Injury and Increased lntracranial Pressure. The respiratory 
depressant effects of Talwin and its potential for elevating cerebro-
spina l fluid pressure may be markedly exaggerated in the pres-
ence of head injury, other intracranial lesions, or a preexisting 
increase in intracranial pressure . Furthermore, Talwin can pro-
duce effects which may obscure the c linical course of patients 
with head injuries. In such patients, Talwin must be used with 
extreme caution and only if its use is deemed essential. 
Usage in Pregnancy. Safe use of Talwin during pregnancy (other 
than labor) has not been established . Animal reproduction studies 
have not demonstrated teratogenic or embryotoxic effects . How-
ever, Talwin should be administered to pregnant patients (other 
than labor) only when, in the judgment of the physician , the po-
tential benefits outweigh the possible hazards. Patients receiving 
Talwin during labor have experienced no adverse effects other 
than those that occur with common ly used analgesics. Talwin 
should be used with caution in women delivering premature 
infants. 
Acute CNS Manifestations. Patients receiving therapeutic doses 
of Talwin have experienced, in rare instances, hallucinations (usu-
ally visual), disorientation, and confusion wh ich have cleared 
spontaneously within a period of hours. The mechanism of this 
reaction is not known . Such patients should be very closely ob-
served and vital signs checked. If the drug is reinstituted it should 
be done with caution since the acute CNS manifestations may recur. 
Usage in Children. Because clinical experience in children under 
12 years of age is limited, administration of Talwin in this age 
group is not recommended. 
Ambulatory Patients. Since sedation, dizziness, and occasional 
euphoria have been noted, ambulatory patients should be warned 
not to operate machinery, drive cars, or unnecessarily expose 
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tion, toxic epidermal necrolysis. ' 
Dosage and Administration: Adults. The usual initial adult dose is 
1 tablet (50 mg.) every three or four hours. This may be increased 
to 2 tablets ( 100 mg.) when needed . Total daily dosage should not 
exceed 600 mg. 
When antiinflammatory or antipyretic effects are desired in addi-
tion to analgesia, aspirin can be administered concomitantly with 
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Overdosage: Manifestations . Clinical experience with Talwin over-
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supportive measurE!s ?hould be employed as indicated. Assisted 
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How Supplied: Tablets, peach color, scored. Each tablet contains 
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A service to medical education from A. H. Robins: ~ G.l :I  Excerpted from Volume 2 oflh'G.I. 
Sen es 
on physical examination 
of the abdomen: 
Normally palpable organs: 
the edge of the liver descending, 
on inspiration, below the costal 
margin (A); the lower pole of the 
right kidney (BJ; the abdominal 
aorta (CJ; the descending colon 
and the sigmoid (DJ; the ascend-
ing colon CE); and occasionally 
the bladder (though rising of 
this organ beyond the pubis 
does not necessarily indicate 
disease) 
Impossible to outline, unless 
diseased, distended or enlarged: 
the gallbladder, pancreas, 
stomach, small intestine, trans-
verse colon and spleen. 
The A . H Robins G I. Series consists of six book-
lets. designed to provide a quick, yet comprehen- I · 1 ' 
sive review of basic procedures and practices in 
G.I. medicine - with particular emphasis on the 
physical examination as performed in the office or ::· 
at bedside If you have teaching respons1bilit1es. '·-.... ""' 
limited quantities are available: Part 1 - Inspection. ~.:.. 
Part 2 - Palpation, Part 3 - Percussion. Part 4 - Auscultation, Part 5-
Abdominal Pain and Part 6 - Different1al Diagnosis of Abdominal 
Disorders. Write to: The Medical Department. A. H Robins Company, 
1407 Cummings Drive. Richmond . Virginia 23220. 
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'1yoscyam1ne sulfate O 1037 mg . 
atropine sulfate 0.0194 mg 
'1yoscine hydrobrom1de 0.0065 mg 
each 
Don natal 
No 2 
0.1037 mg. 
00194mg . 
00065mg. 
phenobarbital (114 gr.) 16.2 mg (Y.1gr.)32.4 mg. 
warning may be habit forming) 
each 
Extentab 
03111 mg. 
0.0582 mg 
0.0195mg. 
CY. gr.) 48.6 mg. 
• 
• Brief summary. Adverse Reactions: Blurring of vision. dry mouth, 
difficult urination, and flushing or dryness of the skin may occur 
on higher dosage levels, rarely on usual dosage. Contraindica-
tions : Glaucoma; renal or hepatic disease; obstructive uropathy 
(for example, bladder neck obstruction due to prostat1c hyper-
trophy); or hypersens1tiv1ty to any of the ingredients. 
A·H·ROBI NS A H Robins Company. Richmond. V1rg1nia 23220 
each tablet. 
capsule or 5 cc. 
teaspoonful 
of elixir (23% alcohol) 
hyoscyam1ne sulfate O 1037 mg. 
atropine sulfate 0 .0194 mg 
hyoscine hydrobrom1de 0 .0065 mg 
each 
Don natal 
No 2 
0.1037mg 
00194mg. 
00065mg. 
phenobarbital (V, gr.) 16.2 mg (Y.! gr.) 32.4 mg. 
(warning may be habit forming) 
each 
Ext en tab 
0.3111 mg 
0.0582 mg 
0.0195mg. 
(%gr.) 48.6 mg. 
• 
• Brief summary. Adverse Reactions: Blurring of vision, dry mouth, difficult urination. and flushing or dryness of the skin may occur 
on higher dosage levels, rarely on usual dosage. Contraindica-
tions: Glaucoma; renal or hepatic disease; obstructive uropathy 
(for example, bladder neck obstruction due to prostatic hyper-
trophy): or hypersensitivity to any of the ingredients. 
A·H·R_O BINS A H Robins Company. Richmond. Virginia 23220 
Before prescribing, please consult 
complete product information, a sum· 
mary of which follows: 
Indications: Tension and anxiety 
states, somatic complaints which are 
concomitants of emotional factors; psy-
choneurotic states manifested by tension, 
anxiety, apprehension, fatigue, depres-
sive symptoms or agitation; symptomatic 
relief of aci.Jte agitation, tremor, delirium 
tremens and hallucinosis due to acute 
alcohol withdrawal ; adjunctively in skele-
tal muscle spasm due to reflex spasm to 
local pathology, spasticity caused by 
upper motor neuron disorders, athetosis, 
stiff-man syndrome, convulsive disorders 
(not for sole therapy). 
Contraindicated: Known hypersensi-
tivity to the drug. Children under 6 
months of age. Acute narrow angle glau-
coma; may be used in patients with open 
angle glaucoma who are receiving appro-
priate therapy. 
Warnings: Not of value in psychotic 
patients. Caution against hazardous 
occupations requiring complete mental 
alertness. When used adjunctively in con-
vulsive disorders, possibility of increase 
in frequency and/ or severity of grand mal 
seizures may require increased dosage of 
standard anticonvulsant medication; 
abrupt withdrawal may be associated 
with temporary increase in frequency 
and/ or severity of seizures. Advise 
against simultaneous ingestion of alcohol 
and other CNS depressants. Withdrawal 
symptoms (similar to those with barbitu-
rates and alcohol) have occurred follow-
ing abrupt discontinuance (convulsions, 
tremor, abdominal and muscle cramps, 
vomiting and sweating) . Keep addiction-
If there's good reason 
to prescribe 
for psychic tension ... 
prone individuals under careful surveil- ·. . 
lance because of their predisposition to ~( ,,....,'°""',......,.,./ 
habituation and dependence. In preg- \ . "}I 
nancy, lactation or women of childbearing · _, 
age, weigh potential benefit against 
possible hazard. 
Precautions: If combined with other 
psychotropics or anticonvulsants, con-
sider carefully pharmacology of agents 
employed; drugs such as phenothiazines, 
narcotics, barbiturates, MAO inhibitors 
and other antidepressants may potentiate 
its action. Usual precautions indicated in 
patients severely depressed, or with latent 
depression, or with suicidal tendencies. 
Observe usual precautions in impaired 
renal or hepatic function. Limit dosage to 
smallest effective amount in elderly and 
debilitated to preclude ataxia or over-
sedation. 
Side Effects: Drowsiness, confusion, 
diplopia, hypotension, changes in libido, 
nausea, fatigue, depression, dysarthria, 
jaundice, skin rash, ataxia, constipation, 
headache, incontinence, changes in sali-
vation, slurred speech, tremor, vertigo, 
urinary retention, blurred vision. Para-
doxical reactions such as acute hyper-
excited states, anxiety, hallucinations, 
increased musc le spasticity, insomnia, 
rage, sleep disturbances, stimulation 
have been reported; should these occur, 
discontinue drug. Isolated reports of neu-
tropenia, jaundice; periodic blood counts 
and liver function tests advisable during 
long-term therapy. 
Roche Laboratories 
When, in spite of counseling, 
the patient's pattern of overreaction to stress 
affects his ability to function 
Dependable response 
1s a good reason 
to consider Valium (diazepam) 
2-mg,5-mg, 
10-mg tablets 
Division of Hoffmann-La Roche Inc. 
Nutley. N.J. 07110 
